Early Phase 2 Clinical Trial of E6011 in Patients With Active Crohn's Disease
Phase: PHASE2
Conditions: Crohn's Disease
Sponsor: EA Pharma Co., Ltd.

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 1 of 80 
 
1.  Title page 
 
 
 
 Clinical trial protocol 
 
Clinical trial protocol  
number:  
E6011-ET2  
Clinical trial name:  
Early phase 2 clinical trial of E6011 in patients with active Crohn’s disease 
 
Sponsor:  
 
 
Sponsor and 
Coordinating 
Investigator’s  
contact information:  
 
EA Pharma Co., Ltd. 
2-1-1 Irifune, Chuo-ku, Tokyo 104-0042 
 
 
See Attachment 2 
IMP name:  
E6011 
 
Target disease:  
Crohn's disease 
 
Clinical trial phase:  
Phase 2 
 
Created on:  
Version 11.0    18 April 2022 
 
 
 
EudraCT Number:  
2018-002109-70 
GCP compliance:  
This clinical trial is to be carried out in strict compliance with the ICH GCP and 
GCP of participating countries, as well as other regulations. All documents and 
materials related to the clinical trial are to be stored in accordance with the 
regulations of regulatory bodies. 
 
Confidentiality:  
The protocol of this clinical trial contains confidential information of the 
Sponsor. The information contained in the protocol must not be read or disclosed 
without obtaining prior written permission of the Sponsor. The information 
contained in the protocol may only be used for the purposes of reviewing or 
carrying out this clinical trial.  

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 2 of 80 
 
Clinical Trial Protocol Approval 
 
 
E6011-ET2  
Early phase 2 clinical trial of E6011 in patients with active Crohn’s disease 
 
 
 
 
 
 
 
 
Clinical Trial Administrative Division Director 
_______________ 
___________________ 
EA PHARMA Co., Ltd. 
DATE 
SIGNATURE 
 
 
 
 
 
 
 
 
 
Clinical Trial Team Lead 
_______________ 
___________________ 
EA PHARMA Co., Ltd. 
DATE 
SIGNATURE 
 
 
 
 
 
  
BIOSTATISTICIAN 
_______________ 
___________________ 
EA PHARMA Co., Ltd. 
DATE 
SIGNATURE 
PPD
PPD
PPD

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 3 of 80 
 
Coordinating Investigator agreement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Coordinating Investigator 
Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PPD

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 4 of 80 
 
Investigator agreement 
 
I confirm that I have read and that I understand this protocol entitled “E6011-ET2. Early phase 2 clinical 
trial of E6011 in patients with active Crohn’s disease”, the investigator brochure, and other product 
information provided by the sponsor. I agree to conduct this study in accordance with the requirements of 
this protocol and also protect the rights, safety, privacy, and well-being of study subjects in accordance 
with the following: 
 
• 
The ethical principles that have their origin in the Declaration of Helsinki. 
• 
International Conference on Harmonisation Harmonised Tripartite Guideline for Good 
Clinical Practice E6. 
• 
All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations. 
• 
Regulatory requirements for reporting serious adverse events defined in this protocol. 
• 
Terms outlined in the Clinical Study Site Agreement.  
 
 
 
 
 
Signature of Investigator 
Date 
 
 
Investigator Name (print or type) 
 
 
 
Investigator’s Title 
 
 
 
Name of Facility 
 
 
 
 
Location of Facility (City) 
 
 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 5 of 80 
 
2.  Clinical trial protocol outline  
 Name of Sponsor 
 EA Pharma Co., Ltd. 
 2-1-1 Irifune, Chuo-ku, Tokyo 104-0042  
 Compound 
 E6011 (First-in-class humanised anti-fractalkine 
antibody) 
 Title of Protocol 
 Early phase 2 clinical trial of E6011 in patients with active Crohn’s disease  
 Study Number 
 E6011-ET2 
 Phase 
 2 
 EudraCT Number 
 2018-002109-70 
 Centers 
 The study will be conducted in anticipated 18 sites in Japan, Czech Republic, Hungary, Poland and 
Russian Federation. 
 Institutional Review Boards / Independent Ethics Committees 
 The study will be evaluated by the Institutional Review Boards / Independent Ethics Committees of all 
the participant centers. 
 Study Monitoring 
 Linical Co. Ltd. 
 10th floor, Shin-Osaka Brick Building, 
 6-1 Miyahara 1-chome, Yodogawa-ku, 
 Osaka 532-0003, Japan 
 https://www.linical.co.jp/en/  
 Study design 
 Multinational, multicentre, randomised, double-blind, placebo-controlled, parallel-group, early phase 2 
clinical trial to be performed in Japan and Europe (Czech Republic, Hungary, Poland, Russian Federation). 
Upon having carried out the screening test within 42 days prior to the start of the IMP administration after 
obtaining consent, this clinical trial will have a double blind period of 12 weeks to assess 
remission-induction, including an open-label rescue period of another 12 weeks (for non-responders to 
Remission-induction), followed by an open-label extension period of additional 40 weeks. All patients will 
have a post-observation period (28 days and 70 days after the last IMP administration) and a 2 years 
follow-up (after the last IMP administration).  
 Disease or disorder under study 
 Patients with active Crohn’s disease  
 Objectives 
 To perform the following evaluation after administering E6011 to patients with moderate to severe active 
Crohn’s disease. 
 Primary objective 
·  To examine the efficacy and safety of E6011 at 12 weeks after administration by means of double-blind 
placebo-controlled trial. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 6 of 80 
 
 Secondary objective 
·  To examine the efficacy and safety of a long-term administration of E6011. 
·  To evaluate the pharmacokinetics and immunogenicity of E6011. 
 Exploratory objective 
  
  
 Anticipated Number of Subjects 
 40 completed patients (20 patients in the E6011 
groups and 20 patients in the placebo group) 
• 
22 Japanese patients : 18 non-Japanese 
patients 
• 
8 biologic-naïve patients 
 Anticipated number of sites 
 18 (Japan, Czech Republic, Hungary, Poland, 
Russian Federation) 
 Dose levels 
 10 mg/kg E6011 dosing solution (approximately 
100 mL) and matching placebo 
 Route of Administration 
 Intravenous infusion pump 
 Duration of Treatment 
 Maximum 64 weeks per subject (52 weeks for 
responders to the remission-induction) 
 Period of Evaluation 
 Screening of 6 weeks 
 Remission-induction of 12 weeks 
 Rescue of 12 weeks 
 Extension of 40 weeks 
 Post-observation of 70 days 
 Follow-up of 2 years  
Main Criteria for Inclusion 
 Subjects who meet all of the following criteria are eligible to participate in this clinical trial. 
(1) Crohn’s disease patients aged 18 or over and under 65 on the date of consent. 
(2) Patients diagnosed on basis of clinical findings, endoscopic findings, etc. with small intestine-type, small 
and large intestine-type, or large intestine-type Crohn's disease at least 12 weeks before giving consent. 
(3) Patients with a baseline (at Week 0 before the start of IMP administration) disease severity ranging 
from moderate to severe. CDAI score between 220 and 450, and a PRO2 score between 14 and 34. 
(4) Patients with a Simple Endoscopic Score for Crohn’s Disease (SES-CD) ≥ 7( or for patients with 
isolated ileal disease, ≥4 in ileum segment)  in the screening period, with one or more ulcers (in 
SES-CD score, ulcer presence subscore ≥ 1 in any segment) assessed by colonoscopy and confirmed 
by a centralised review. 
(5) Patients who received adrenocorticosteroids or immunomodulators in the past, but showed no 
therapeutic response (insufficient response) or the drugs were not tolerated (intolerance). Alternatively, 
patients who cannot taper adrenocorticosteroids (dependence). Alternatively, patients who showed no 
therapeutic response after administering biologic(s) (primary nonresponse), patients who initially 
showed therapeutic response but it lessened or disappeared afterwards (secondary nonresponse), or 
patients who did not tolerate the drug (intolerance). (Detailed criteria are described in Attachment 7 
and Attachment 8). 
C
C

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 7 of 80 
 
(6) If the patients are taking 1,200 kcal/day or less enteral nutrition, the dosage and administration have 
not changed for at least 4 weeks prior to the start of the IMP administration. 
(7) If the patients are taking aminosalicylic acid (5-ASA), salazosulfapyridine, or antibiotics for the 
treatment of Crohn's disease (metronidazole, ciprofloxacin, etc.), the dosage and administration have 
not changed for at least 4 weeks prior to the start of the IMP administration. 
(8) If the patients are taking under 30 mg/day of oral prednisolone (or equivalent adrenocorticosteroid) or 
9 mg/day or less of oral budesonide, the dosage and administration have not changed for at least 4 
weeks prior to the start of the IMP administration. 
(9) If the patients are taking azathioprine (AZP), 6-mercaptopurine (6-MP) or methotrexate (MTX), the 
dosage and administration have not changed for at least 8 weeks prior to the start of the IMP 
administration. 
(10) Patients who have received a sufficient explanation about the compliance rules of this clinical trial, 
who are willing to comply with them, and who are able to do so. 
(11) Patients who voluntarily gave a written consent to participate in this clinical trial. 
 Main Criteria for Exclusion: 
 Patients who meet any of the following criteria shall be excluded from this clinical trial. 
(1) Patients diagnosed with ulcerative colitis or indeterminate colitis (refers to cases in which there is a 
difficulty distinguishing between Crohn’s disease and ulcerative colitis, intermediate colitis). 
(2) Patients diagnosed with gastrointestinal epithelial dysplasia. 
(3) Patients who have an abscess or are suspected to have one (however, patients with anal abscess 
whose symptoms are stable with treatment, such as drug treatment or drainage, are not excluded). 
(4) Patients with an artificial anus, ileo-anal pouch or fistula (however, patients with fistula-in-ano whose 
symptoms are stable with treatment, such as drug treatment or drainage, are not excluded). 
(5) Patients with symptomatic or high-grade gastrointestinal stenosis (patients who require expansion by 
endoscopy or who have SES-CD score stenosis sub-score of 3, etc.). 
(6) Patients who, after undergoing small bowel resection, have been diagnosed with a short bowel 
syndrome, which makes maintaining caloric intake difficult. 
(7) Patients who have newly started seton drainage treatment within 12 weeks prior to the start of the 
IMP administration. 
(8) Patients who have undergone bowel resection or a gastrointestinal surgery within 24 weeks prior to 
the start of the IMP administration. 
(9) Patients who tested positive for C. difficile toxin test in the screening period. 
(10) Patients who tested positive for HIV, hepatitis B surface antigen (HBsAg), hepatitis B surface 
antibody (anti-HBs), hepatitis B core antibody (anti-HBc), hepatitis B virus DNA (HBV-DNA), 
hepatitis C virus antibody (anti-HCV), or human T cell leukemia virus type 1 antibody (anti-HTLV-1) 
in the screening period (however, this excludes patients who tested positive only for anti-HBs, clearly 
shown to be due to hepatitis B vaccination). Patients who tested negative for HBsAg and quantitative 
HBV-DNA and positive for anti-HBc antibody and/or anti-HBs antibody may participate in the 
clinical trial as long as the Principal Investigator or Sub-investigator takes proper measures such as 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 8 of 80 
 
monitoring HBV-DNA based on (not restricted to the following) 
• For Japan: Guidelines for measures against hepatitis B arising due to immunosuppression or 
chemotherapy 
• For Poland: Recommendations for the treatment of chronic viral hepatitis B in 2018 
by Polish Group of Experts for HBV 
• For Hungary: Diagnosis and treatment of chronic hepatitis B and D. Hungarian national 
consensus guideline 
• For Czech Republic: EASL (European Association for the Study of the Liver) 2017 Clinical 
Practice Guidelines on the management of hepatitis B virus infection   
• For Russian Federation: Order of Ministry of Health of Russian Federation #786н “On approval of 
the standard of specialized medical care for chronic viral hepatitis B" dd. 09.11.2012 
In addition, patients who tested positive for HCV antibody and who were at least 24 weeks 
post-treatment may participate in the clinital trial as long as negative HCV-RNA is confirmed during 
the screening period. 
(11) Patients with positive or repeated indeterminate (inconclusive) results on the TB test (QuantiFERON 
® -TB Gold test or T-SPOT ® TB test). However, patients with indeterminate (inconclusive) results on 
repeated tests may be included in this clinical trial if they are started on prophylactic isoniazid least 21 
days prior to the start of IMP administration. (The dose is generally 300 mg/day. If the patient has a 
low body weight, the dose is to be 5 mg/kg a day. The drug is administered for approximately 9 
months.) Prophylactic treatment should be given in accordance with the local guidelines. 
(12) Patients with findings showing a history of tuberculosis on a chest X-ray test in the screening period. 
(13) Patients with findings of neurological symptoms such as motor impairment, cognitive disorder, 
language disorder or dysphagia in the evaluations during the screening period. 
(14) Patients with a WBC count of less than 3,000/μL or blood CD4+ cell count under 200/μL in the 
screening period tests. 
(15) Patients with a medical history of clinically significant vasculitis. 
(16) Acute myocardial infarction, unstable angina pectoris, cerebral infarction, and symptomatic cerebral 
haemorrhage patients. 
(17) Patients whose AST or ALT was more than three times the upper normal limit in the screening period 
tests or patients whose serum creatinine level was more than 1.5 times the upper normal limit in the 
screening period tests. 
(18) Patients with a QTcF exceeding 450 ms repeatedly in standard 12-lead ECG tests in the screening 
period tests. 
(19) Patients who have undergone cytoapheresis (granulocytapheresis; GCAP) within 2 weeks prior to the 
start of the IMP administration. 
(20) Patients who required any one of the following treatments of infection; "hospitalization within 4 
weeks prior to the start of IMP administration", "intravenous treatment of antibiotics (including 
antiviral drugs) within 4 weeks prior to the start of IMP administration", or "oral treatment of 
antibiotics (including antiviral drugs) within 2 weeks prior to the start of IMP administration" 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 9 of 80 
 
Furthermore, with regard to the novel coronavirus infection (COVID-19), patients who required any 
one of the following treatments; “hospitalization within 4 weeks prior to the start of IMP 
administration”, “any intravenous treatment within 4 weeks prior to the start of IMP administration” or 
“any oral treatment within 2 weeks prior to the start of IMP administration”. 
(21) Patients who received total parenteral nutrition (TPN), peripheral parenteral nutrition (PPN), or 
enteral nutrition exceeding 1200 kcal/day within 4 weeks prior to the start of the IMP administration. 
(22) Patients who received ≥30 mg/day of oral prednisolone (or an equivalent adrenocorticosteroid), 
adrenocorticosteroid injection, enema or suppository within 4 weeks prior to the start of the IMP 
administration. 
(23) Patients who received cyclosporine, mycophenolate mofetil, or tacrolimus within 8 weeks prior to the 
start of the IMP administration (excluding topical use). 
(24) Patients who received adalimumab, infliximab, certolizumab pegol, vedolizumab or ustekinumab 
(including biosimilars) within 8 weeks prior to the start of the IMP administration. 
(25) Patients vaccinated with live vaccines within 12 weeks prior to the start of the IMP administration or 
patients who received a vaccine that is considered to have a risk of infection, such as a virus vector 
vaccine that uses a virus that retains its ability to proliferate within 12 weeks prior to the start of the 
IMP administration 
(26) Patients who received an immunoglobulin preparation or a blood product within 24 weeks prior to the 
start of the IMP administration. 
(27) Patients who have received natalizumab or E6011 in the past 
(28) Patients with a history of a malignant tumour, lymphoma, leukemia, or lymphoproliferative disorders, 
or with complications thereof. However, this does not include completely resected skin cancers 
(epithelial cell cancers or basal cell cancers) and cervical cancers with no metastasis or recurrence 
observed for 5 more years at the time of giving consent. 
(29) Patients with immunodeficiency or a history of HIV infection. 
(30) Patients with a history of severe allergy (shock, anaphylaxis-like symptoms). 
(31) Patients currently taking part in another clinical trial (including the post-observation period), or 
patients who were participating in another trial using an IMP or investigational medical device within 
28 days (or within five times the length of the half-life period of the IMP, whichever is longer) prior to 
giving consent. 
(32) Patients who received a faecal microbiota transplant (FMT), mesenchymal stem cell, etc. within 24 
weeks prior to giving consent. 
(33) Female patients of childbearing potential who had a positive result on the pregnancy test at screening 
or baseline, as well as lactating patients. 
(34) Female patients of childbearing potential who: 
• 
have not been on a highly effective method of contraception within 28 days prior to the start of 
IMP administration. The following are highly effective contraception methods: 
–  Sexual abstinence (if preferred by subjects as their regular lifestyle) 
–  Use of intrauterine device (IUD)  

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 10 of 80 
 
– Contraceptive implant 
–  Use of oral contraceptives 
 (The same oral contraceptive is to be used at a set dose for more than 28 days prior to the start of 
the IMP administration, and continued throughout the clinical trial and for 70 days after the last 
administration of the IMP) 
–  The male partner has undergone vasectomy and azoospermia has been confirmed 
• 
Patients who do not agree to continue using one of the highly effective contraception methods 
described above throughout the clinical trial and for 70 days after the last administration of the 
IMP 
• 
If the use of the aforementioned contraception methods is not appropriate or not allowed, the 
patients are required to consent to use another medically appropriate contraception method, i.e. a 
double-barrier method (combined use of a condom and contraceptive diaphragm, or a 
spermicide-containing cervical/vault cap, etc.) 
• 
All females are deemed to have childbearing potential. However, postmenopausal women 
(menopausal age patients who have not menstruated for at least 12 consecutive months, which 
has been confirmed not to be due to other factors, or is not suspected to be due to other factors) 
and women who have undergone surgical sterilization (patients who have undergone bilateral 
tubal ligation, hysterectomy, or bilateral oophorectomy more than one month prior to the IMP 
administration) are excluded from this rule. 
(35) Potential male patients with female partners of childbearing potential: 
• 
that have not undergone proper vasectomy (azoospermia can not be confirmed) who (or whose 
partners) do not agree to use contraception employing one of the methods listed in the exclusion 
criteria (34) during the clinical trial and for 70 days after the last administration of the IMP 
(however, if the female partner does is not of childbearing potential, the subject can participate in 
the trial). 
• 
patients whose female partner is pregnant and do not agree to use latex or synthetic condoms 
during the clinical trial and for 70 days after the last administration of the IMP. 
• 
the patients must not donate sperm during the clinical trial and for 70 days after the last 
administration of the IMP. 
(36) Patients who were judged to be unsuitable for participation in this clinical trial by the Principal 
Investigator or Sub-investigator.  
Main Criteria for Evaluation and Analysis 
 Efficacy analysis will be performed using the FAS as the primary analysis set, while the PPS will be used 
as a supplementary analysis set. 
 
Analysis of primary endpoint 
  For Week 12 CR100 rate, the Bayesian posterior distribution of the difference in the CR100 rate at 
Week 12 between the E6011 group and the placebo group is to be calculated. If there was a 50% or more 
probability of the difference between both groups being 25% or more, the efficacy of E6011 is confirmed. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 11 of 80 
 
Noninformative prior distribution is to be used for both the E6011 group and the placebo group.  
 Subjects with missing primary endpoint data by Week 12 after administration due to premature 
discontinuation or other reasons are treated as treatment failures (non-responder imputation [NRI]). 
Analysis of secondary endpoints 
  CDAI response rate (CR70, CR100 (excluding Week 12)) and remission rate are to be calculated by 
treatment group and evaluation time. Summary statistics for CDAI value, change and percent change 
from baseline are also to be calculated by treatment group and evaluation time. 
  PRO2 response rate (PRO2-CR5, PRO2-CR8) and remission rate are to be calculated by treatment 
group and evaluation time. Summary statistics for PRO2 value, change and percent change from 
baseline are also to be calculated by treatment group and evaluation time. 
  SES-CD endoscopic response rate and endoscopic remission rate are to be tabulated by treatment 
group and evaluation time. Summary statistics for SES-CD value, change and percent change from 
baseline are also to be calculated by treatment group and evaluation time. 
  Steroid-free remission rate and steroid-free response rate in subjects concomitantly using 
adrenocorticosteroids is to be tabulated by treatment group and evaluation time. Summary statistics for 
steroid dosage, change and percent change from baseline are also to be calculated for each treatment 
group and evaluation time. 
Pharmacokinetics 
Drug concentration is to be analysed using the drug concentration analysis set. Summary statistics for 
serum E6011 concentration are to be calculated for each specified time. Serum E6011 concentration-time 
profile is also to be created. 
Biomarkers, pharmacogenomics/pharmacogenetics 
Biomarkers, pharmacogenomics/pharmacogenetics are to be analysed using the pharmacodynamic 
analysis set. Summary statistics for serum total FKN concentration, faecal calprotectin and serum CRP 
concentration measured values, change and percent change from baseline are to be calculated by treatment 
group and evaluation time. 
 
 Details and results of the analysis of blood CD16+ monocytes, etc., blood CD16+ 
monocyte, etc. genetic markers and blood biomarkers (comprehensive proteome analysis) using the 
residual serum collected for this study are to be recorded in a separately created report, and not included in 
the Clinical Study Report. 
Immunogenicity 
Immunogenicity is to be analysed using the safety analysis set. Incidence and ratio of serum anti-E6011 
antibodies are to be calculated by treatment group and evaluation time. If anti-E6011 antibodies are 
confirmed, frequency and ratio of their neutralizing activity (if present) and isotypes are to be calculated. 
Safety 
Safety is to be analysed using the safety analysis set. Summary statistics related to safety data (sample size, 
mean value, standard deviation, median value, minimum and maximum as continuous variables; sample size 
CCI

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 12 of 80 
 
and ratio as categorical variables) are to be calculated by each treatment group based on the treatment that was 
administered. Safety endpoints include adverse events, clinical examination values, vital signs, weight, physical 
examination, standard 12-lead ECG tests, neurological symptoms and blood CD4+ cell count. 
  Incidence rate of adverse events that occurred after the IMP administration is to be calculated by 
treatment group. 
  Summary statistics for measured clinical examination values, vital signs and CD4+ cell count, as well 
as their change from baseline, are to be calculated by treatment group. 
  For standard 12-lead ECG test findings and neurological symptoms, the numbers and rates are shown 
in the shift table by each treatment group and by normal and abnormal findings. 
 Interim analysis 
 No interim analysis is planned in this clinical trial.  
 Sample size Justification 
 The number of subjects in this clinical trial was determined considering operating characteristics 
pertaining to a simulation efficacy evaluation, with reference to efficacy performance in the 
E6011-J081-101 study, as well as efficacy performance of similar drugs. With 20 subjects allotted to each 
group, if the actual difference in CR100 response rate between the E6011 group and placebo group is 40% 
or more, the probability of confirming the efficacy of E6011 is above 80%.  
 Study schedule and anticipated date of completion 
 Recruitment: September 2018 to October 2021 
 Treatment: October 2018 to April 2022 
 Follow-up: Jun 2021 to April 2024 
 Close-out: May 2024 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 13 of 80 
 
3.  Table of Contents 
1. Title page .................................................................................................................................................... 1 
Clinical Trial Protocol Approval ..................................................................................................................... 2 
Coordinating Investigator agreement ............................................................................................................. 3 
Investigator agreement ................................................................................................................................... 4 
2. Clinical trial protocol outline ...................................................................................................................... 5 
3. Table of Contents ...................................................................................................................................... 13 
List of Tables Found in the Document .......................................................................................................... 16 
List of Figures Found in the Document ........................................................................................................ 17 
List of Appendices ........................................................................................................................................ 18 
4. List of Abbreviations ................................................................................................................................ 19 
5. Ethics ........................................................................................................................................................ 21 
5.1 IRB/IEC .............................................................................................................................................. 21 
5.2 Ethical implementation of the clinical trial......................................................................................... 22 
5.3 Information provided to subjects and informed consent..................................................................... 22 
6. Principal Investigators and the Clinical Research Associates ................................................................... 23 
7. Introduction .............................................................................................................................................. 23 
8. Clinical trial objective .............................................................................................................................. 24 
8.1 Primary objective ................................................................................................................................ 24 
8.2 Secondary objective ............................................................................................................................ 24 
8.3 Exploratory objective ......................................................................................................................... 24 
9. Clinical trial plan ...................................................................................................................................... 25 
9.1 General clinical trial design and plan ................................................................................................. 25 
9.1.1 Screening period .......................................................................................................................... 26 
9.1.2 Remission-induction period ......................................................................................................... 26 
9.1.3 Rescue period .............................................................................................................................. 27 
9.1.4 Extension period .......................................................................................................................... 27 
9.1.5 Post-observation period ............................................................................................................... 27 
9.1.6 Follow-up period ......................................................................................................................... 27 
9.2 Discussion of the clinical trial design, including control group selection .......................................... 27 
9.3 Selection of clinical trial population ................................................................................................... 28 
9.3.1 Inclusion criteria .......................................................................................................................... 29 
9.3.2 Exclusion criteria: ........................................................................................................................ 30 
9.3.3 Termination of subject treatment or evaluation ........................................................................... 33 
9.4 Treatment method ............................................................................................................................... 34 
9.4.1 IMP administration method ......................................................................................................... 34 
9.4.2 IMP identification ........................................................................................................................ 35 
9.4.2.1 E6011 chemical name, structural formula, etc. ..................................................................... 35 
9.4.2.2 Control drug .......................................................................................................................... 35 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 14 of 80 
 
9.4.2.3 IMP label .............................................................................................................................. 36 
9.4.2.4 Storage conditions ................................................................................................................ 36 
9.4.3 Method of allocating subjects to treatment groups ...................................................................... 36 
9.4.4 Dosage selection in the clinical trial ............................................................................................ 36 
9.4.5 Dosage selection for each subject and administration period ...................................................... 37 
9.4.6 Blinding ....................................................................................................................................... 37 
9.4.6.1 Blinding method ................................................................................................................... 38 
9.4.6.2 Maintenance of blinding ....................................................................................................... 38 
9.4.6.3 Reporting blinded item measurement results ........................................................................ 38 
9.4.7 Prior treatment and concomitant treatment .................................................................................. 39 
9.4.7.1 Prohibited concomitant therapies and concomitant drugs .................................................... 39 
9.4.8 Compliance with the treatment method ....................................................................................... 40 
9.4.9 Supply and management of IMP ................................................................................................. 41 
9.5 Clinical trial methodology .................................................................................................................. 42 
9.5.1 Assessment items ......................................................................................................................... 42 
9.5.1.1 Demographic characteristics and assessment method .......................................................... 42 
9.5.1.2 Assessment items and method during the screening period .................................................. 42 
9.5.1.3 Assessment items and method for efficacy evaluations ........................................................ 43 
9.5.1.4 Assessment items and method for pharmacokinetic, immunogenicity, biomarker and 
pharmacogenomic/pharmacogenetic evaluations ............................................................................. 45 
9.5.1.5 Assessment items and method for safety evaluation............................................................. 47 
9.5.1.6 Other assessment items ......................................................................................................... 53 
9.5.2 Observation/assessment items and the study schedule ................................................................ 53 
9.5.2.1 Study schedule ...................................................................................................................... 53 
9.5.2.2 Total amount of blood sampled............................................................................................. 59 
9.5.3 Suitability of assessment items .................................................................................................... 61 
9.5.4 Reporting of SAEs, pregnancy and other important AEs ............................................................ 62 
9.5.4.1 Reporting of SAEs ................................................................................................................ 62 
9.5.4.2 Reporting of pregnancy and breastfeeding ........................................................................... 62 
9.5.4.3 Reporting of other notable occurrences ................................................................................ 63 
9.5.4.4 Emergency reporting ............................................................................................................ 63 
9.5.4.5 Unblinding ............................................................................................................................ 63 
9.5.4.6 Reporting of AEs to regulatory authorities ........................................................................... 64 
9.5.5 Subject completion and withdrawal ............................................................................................. 64 
9.5.6 IMP abuse (or IMP diversion to non-subjects) ............................................................................ 64 
9.5.7 Checks for medical care at another department/another hospital ................................................ 65 
9.6 Quality assurance of the data .............................................................................................................. 65 
9.6.1 Data collection ............................................................................................................................. 65 
9.6.2 Management of clinical trial data ................................................................................................ 65 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 15 of 80 
 
9.7 Statistical method ............................................................................................................................... 65 
9.7.1 Statistical and analysis plan ......................................................................................................... 66 
9.7.1.1 Endpoints .............................................................................................................................. 66 
9.7.1.2 Definition of the analysis population .................................................................................... 66 
9.7.1.3 Breakdown of subjects .......................................................................................................... 67 
9.7.1.4 Characteristics of demographic and pre-treatment values .................................................... 67 
9.7.1.5 Prior treatment and concomitant treatment ........................................................................... 67 
9.7.1.6 Efficacy analysis ................................................................................................................... 67 
9.7.1.7 Analysis of pharmacokinetics, pharmacodynamics, pharmacogenomics/pharmacogenetics 
and other biomarker evaluations ....................................................................................................... 68 
9.7.1.8 Safety analysis ...................................................................................................................... 69 
9.7.1.9 Other analyses ....................................................................................................................... 70 
9.7.1.10 Analysis of the entire dosing period ................................................................................... 70 
9.7.1.11 Analysis of the follow-up period ......................................................................................... 70 
9.7.2 Target sample size ........................................................................................................................ 71 
9.7.3 Interim analysis ............................................................................................................................ 71 
9.7.4 Other key statistical and analytical considerations ...................................................................... 71 
9.7.5 Changes to the analysis plan ........................................................................................................ 71 
10. List of cited literature ............................................................................................................................. 72 
11. Procedures and instructions (action plan) ............................................................................................... 74 
11.1 Changes in the clinical trial protocol ................................................................................................ 74 
11.2 Conformity to the clinical trial protocol ........................................................................................... 74 
11.3 Monitoring procedures ...................................................................................................................... 74 
11.4 Data recording .................................................................................................................................. 75 
11.5 Source data specification .................................................................................................................. 75 
11.6 Retention of records .......................................................................................................................... 76 
11.7 Audit procedures and inspections ..................................................................................................... 76 
11.8 IMP handling .................................................................................................................................... 76 
11.9 Public release of the clinical trial results .......................................................................................... 77 
11.10 Disclosure of information/results and confidentiality ..................................................................... 77 
11.11 Discontinuation of clinical trial....................................................................................................... 77 
11.12 Compensation for health damages .................................................................................................. 77 
12. Appendix................................................................................................................................................. 78 
13. Attachments ............................................................................................................................................ 80 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 16 of 80 
 
 
 List of Tables Found in the Document 
 
Table 1 IMP administration method ................................................................................................. 34 
Table 2 IMP ...................................................................................................................................... 35 
Table 3 Laboratory Tests .................................................................................................................. 51 
Table 4 E6011-ET2 Study Schedule (All Subjects) .......................................................................... 54 
Table 5 The total amount of blood sampled (Responders) ............................................................... 59 
Table 6 The total amount of blood sampled (Non-responders) ........................................................ 60 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 17 of 80 
 
 
 List of Figures Found in the Document 
 
Figure 1 Clinical trial design ............................................................................................................ 26 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 18 of 80 
 
 
 List of Appendices 
 
Appendix 1 Collection, handling, use, storage and security of samples for pharmacodynamic, 
pharmarcogenomic, and biomarker evaluations and protection of subjects’ privacy ........................... 78 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 19 of 80 
 
 
 
4.  List of Abbreviations  
 Abbreviations  
 Unabbreviated Terms (English)  
 ALP  
 alkaline phosphatase  
 ALT  
 alanine aminotransferase (SGPT)  
 5-ASA  
 5-amino salicylic acid  
 AST  
 aspartate aminotransferase (SGOT)  
 ATC  
 anatomical therapeutic chemical  
 AZP  
 azathioprine  
 BUN  
 blood urea nitrogen  
 CDAI  
 Crohn’s disease activity index  
 CK  
 creatine kinase  
 CR  
 Clinical response  
 CRO  
 contract research organization  
 CRP  
 C-reactive protein  
 CT  
 computed tomography  
 CX3CR1  
 CX3C motif chemokine receptor 1 (receptor of fractalkine)  
 DNA  
 deoxyribonucleic acid  
 eCRF  
 electronic Case Report Form  
 EMA  
 European Medicines Agency  
 ECCO  
 European Crohn’s and Colitis Organization  
 FAS  
 full analysis set  
 FKN  
 fractalkine  
 FMT  
 faecal microbiota transplantation  
 GCP  
 good clinical practice  
 GCAP  
 granulocytapheresis  
  GTP  
  -glutamyl transpeptidase  
 HBc  
 hepatitis B virus core  
 HBs  
 hepatitis B virus surface  
 HBV  
 hepatitis B virus  
 HCV  
 hepatitis C virus  
 HIV  
 human immunodeficiency virus  
 HTLV-1  
 human T cell lymphotropic virus-1  
 IBD  
 inflammatory bowel disease  
 ICH  
 The International Council for Harmonization of Technical Requirements 
for Pharmaceuticals for Human Use  
 ID  
 identification  
 IEC  
 Independent Ethics Committee  
 IgG  
 immunoglobulin G  
 IL-12/23  
 Interleukin 12/23  
IRB 
Institutional Review Board 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 20 of 80 
 
 IUD  
 intrauterine device  
 IV  
 intravenous  
 IVRS  
 interactive voice response system  
 IWRS  
 interactive web response system  
 JCV  
 JC virus  
 LDH  
 lactate dehydrogenase  
 LLT  
 lowest level term  
 LNH  
 low normal high  
 MedDRA  
 medical dictionary for regulatory activities  
 6-MP  
 6-mercaptopurine  
 MRI  
 magnetic resonance imaging system  
 MS  
 multiple sclerosis  
 MTX  
 methotrexate  
 NRI 
 Non-Responder Imputation 
 PD  
 pharmacodynamics  
 PK  
 pharmacokinetics 
 PML  
 progressive multifocal leukoencephalopathy  
 POC  
 proof of concept  
 PPN  
 peripheral parenteral nutrition  
 PPS  
 per protocol set  
 PRO2  
 patient reported outcome 2  
 PT  
 preferred term  
 QOL  
 quality of life  
 QTcF  
 average time-matched QT corrected by the Fridericia formula  
 SC  
 subcutaneous  
 SES-CD  
 simple endoscopic score for Crohn’s disease 
 SI 
 Le Systeme international d'uniyes 
 SOC 
 system organ class 
 SOP 
 standard operating procedures 
 SUSAR 
 suspected unexpected serious adverse reaction 
 TB 
 tuberculosis 
 TEAE 
 treatment emergent adverse events 
 TNFα 
 tumour necrosis factor α 
 TPN 
 total parenteral nutrition 
 URL 
 uniform resource locator 
 WHO DD 
 world health organization drug dictionary  
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 21 of 80 
 
 
5.  Ethics 
5.1   IRB/IEC 
 The protocol, informed consent form and other related documents must be reviewed and approved by 
an IRB/Independent Ethics Committee (IEC) established and operated in accordance with the ICH GCP 
(Section 3) and regulations applicable in each respective region. In order to revise the protocol or change 
the informed consent form, it is necessary to undergo another review by the IRB/IEC and obtain approval 
(however, this excludes changes in administrative items such as change of the monitor or telephone 
number). A document certifying compliance with the ICH GCP and regulations applicable in each region 
in establishing, reviewing and operating the IRB/IEC is to be submitted to the Sponsor. 
 The Principal Investigator (or, in accordance with the regulations of each region, the head of Clinical 
Trial Centre) is to obtain an approval document from the chairperson of the IRB/IEC before starting the 
clinical trial. The Sponsor (or its representative) is to obtain said document before delivering the IMP to 
the Clinical Trial Centre (ICH GCP, Section 4.4). Should the IRB/IEC decide to suspend or discontinue the 
clinical trial, the Principal Investigator (or, in accordance with the regulations of each region, head of 
Clinical Trial Centre) is to promptly report this to the Sponsor. 
 The Principal Investigator or the Sponsor (depending on the regulations of each region), is to report to 
the IRB/IEC once a year (or in accordance with the regulations) on the clinical trial implementation status. 
When the Principal Investigator is required to report to the IRB/IEC, in addition to sending the report to 
the IRB/IEC, he/she shall submit a copy of the report to the Sponsor. The Principal Investigator or the 
Sponsor, in addition to making periodic reports as stipulated by the regulations of each region, shall report 
to the IRB/IEC (according to the regulations of each region, the report is made either via the head of the 
Clinical Trial Centre after notifying the Principal Investigator and the head of the Clinical Trial Centre, or 
directly to the IRB/IEC) all reportable adverse events according to the ICH GCP and the IRB/IEC 
procedure manual. Moreover, the Principal Investigator is to report to the IRB/IEC and the Sponsor 
through the head of Clinical Trial Centre a summary of the clinical trial results upon completion of the 
clinical trial. 
 In Europe, the Principal Investigator is to report to the IEC a summary of the clinical trial results upon 
completion of the clinical trial. The Sponsor is to notify the IEC and competent authority of the clinical 
trial completion within 90 days from the completion. Clinical trial completion shall be marked by the date 
of the last follow-up visit of the last subject in this clinical trial. The Sponsor is to report to the IRB/IECthe 
summary of the clinical trial results as well. 
 If the clinical trial is prematurely discontinued or temporarily suspended, the Principal Investigator is 
to notify the IRB/IEC and competent authority of this fact within 15 days. A detailed explanation of the 
reason for the discontinuation or suspension is to be provided in writing. 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 22 of 80 
 
5.2   Ethical implementation of the clinical trial 
 This clinical trial is to be carried out in compliance with the Sponsor’s (or its representative's) SOP that 
was created in accordance with the following guidelines, etc. 
 
 Ethical principles based on the WMA Declaration of Helsinki (Ethical Principles for Medical 
Research Involving Human Subjects) 
 
 ICH GCP (CPMP/ICH/135/95) 
 
 All clinical trials carried out in European countries shall adhere to European Good Clinical Practice 
Directive 2005/28/EC and European Clinical Trial Directive 2001/20/EC. All suspected unexpected 
serious adverse reactions (SUSARs) are to be reported to competent authorities of involved European 
countries in accordance with the regulations 
 
5.3   Information provided to subjects and informed consent 
 The Principal Investigator, in accordance with the ICH GCP (Section 4) and regulations of each region, 
shall create an informed consent form with the help of the Sponsor and obtain approval of the IRB/IEC. 
 The Principal Investigator or the Sub-investigator is required to explain to each subject (or 
representative) the clinical trial content, purpose, procedures, scheduled participation period, anticipated 
clinical benefits, risks and inconveniences, whether there are other treatment methods available to the 
subject, and the fact that the subject's confidentiality will be protected. The Principal Investigator or the 
Sub-investigator shall also explain that the subject’s participation in the clinical trial is voluntary, that the 
subject may refuse to participate or withdraw from the trial at any time, and that the refusal or withdrawal 
will not adversely affect the subject’s subsequent medical treatment or relationship with the doctor. A 
document written in a non-specialised language shall be used in the above informed consent explanation. 
 Before participation in the trial, the subject is to sign his/her name and date the informed consent form 
that has been approved by the IRB/IEC/IEC. The informed consent form must also be signed and dated by 
the Principal Investigator or authorized Sub-investigator who conducted the informed consent discussion. 
The subject needs to understand the explanation before writing his/her signature and date on the form. The 
subject is to receive a copy of the signed informed consent form and subject information sheet. If the 
subject is unable to read the informed consent form, an impartial witness needs to be present throughout 
the entire informed consent explanation process. The witness is to read out and explain to the subject the 
informed consent form and other information for the subject contained in documents. Afterwards, the 
subject is to give a verbal consent to participate in the study. Then, the witness is to write his/her signature 
and date on the consent form after the subject, if he/she is able to, has written his/her signature and date on 
the form. Before carrying out any assessments and evaluations related to this clinical trial, it is necessary to 
confirm whether the subject has signed the informed consent form. The subject may not be enrolled in the 
clinical trial before signing his/her informed consent. 
 The original of all signed informed consent form are to be stored at the Clinical Trial Centre, and this is 
to be verified by the Sponsor. 
 If any information that might affect the subject’s willingness to continue participation in this clinical 
trial becomes available, the information is to be promptly provided to the subject, and the fact of its 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 23 of 80 
 
provision is to be recorded in writing. 
 In cases where the consent of a legally acceptable representative is required, if the subject understands 
the fact of his/her participation in the clinical trial, the Principal Investigator or Sub-investigator shall use 
the informed consent form to explain about the clinical trial to the subject in the same way he did to the 
legally acceptable representative, and obtain the subject’s signature. Subjects who are unable to sign the 
consent form are to verbally confirm their willingness to participate, which is to be recorded in the consent 
form. 
 
6.  Principal Investigators and the Clinical Research Associates 
 This clinical trial will be conducted at 18 Clinical Trial sites (anticipated) in Japan, Europe and Russia 
by Principal Investigators selected by the Sponsor (Attachment 1). 
 The name and contact information (telephone number and FAX number) of the Sponsor and Contract 
Research Organization (CRO) are listed in Attachment 2. 
 
7.  Introduction 
 Crohn’s disease is one of inflammatory bowel diseases (IBD) that causes longitudinal ulcers in the 
small and large intestine, which leads to abdominal pain, diarrhoea, fever, melena and weight loss. The 
disease commonly occurs in people in their 10s and 20s. The patients experience repeated recurrences that 
cause a progressive destruction of the gastrointestinal tract tissue1 , which ultimately necessitates a 
resection. The cause of Crohn’s disease is not known, but it is thought to be a multifactorial disease caused 
by an intricate combination of genetic factors, environmental factors such as diet, and increased 
inflammatory cytokines such as tumour necrosis factor (TNFα) associated with immunological 
abnormality2 . The number of Crohn's disease patients in Japan has been growing each year, with 
approximately 41,000 patients as of present (2014, number of medical care certificate holders). This 
disease is especially prevalent in Europe and America, where the incidence rate is high. 
 At present, there is no cure for Crohn's disease, and the goal of the treatment is to prevent recurrence, 
control disease activity and maintain clinical remission. Biologics such as anti-TNF α antibody products 
have greatly changed the therapeutic system, as they were found to be effective in Crohn's disease patients 
who did not derive sufficient benefits from existing therapeutic drugs, including steroids or 
immunomodulators. However, there are also patients who do not respond to such biologics, patients for 
whom the therapeutic efficacy decreases 3 , and patients for whom administration cannot be continued due 
to allergic reactions. As such, it cannot be said that biologics sufficiently meet medical needs. 
Consequently, there is a strong demand for development of drugs with new mechanisms of action that are 
highly effective and safe. 
 E6011 is the world’s first humanised anti-fractalkine (FKN) monoclonal antibody created by Eisai’s 
KAN Research Institute, Inc. FKN has a dual effect of modulating leukocyte migration and acting as an 
adhesion molecule, and plays an important role in leukocyte infiltration in the inflamed tissue4 . From the 
fact that anti-FKN antibody suppressed damage to large intestine in mouse models of T cell transfer colitis 
and oxazolone-induced colitis, it has been suggested that FKN plays a role in intestinal inflammation 5 . In 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 24 of 80 
 
addition, FKN expression and FKN receptor (CX3CR1) positive cells are increased in Crohn's disease 
patients’ peripheral blood and inflamed gastrointestinal tract tissue, which points out to a relationship 
between the pathology of Crohn's disease and FKN6 ,7 ,8 ,9 . Based on the above, it is expected that E6011, 
by inhibiting FKN function, will suppress migration and infiltration of lymphocytes and monocytes into 
inflammatory sites, thus reducing inflammatory lesions in the gastrointestinal tract of Crohn’s disease 
patients. 
 At present, a phase 1 study of single intravenous (IV) E6011 administration in Japanese healthy adult 
subjects (E6011-J081-001, hereinafter “Study 001”) and a phase 1 study of single subcutaneous 
administration (SC) in healthy Japanese adult subjects (E6011-J081-002, hereinafter “Study 002”) have 
been completed. No adverse events that raise concerns in terms of safety and tolerability were observed 
with the dosages used in Study 001 (IV: 0.0006 to 10 mg/kg) and Study 002 (SC: 50 to 400 mg). 
 In a phase 1/2 study of repeated intravenous E6011 administration in Japanese subjects with Crohn's 
disease (E6011-J081-101, hereinafter “Study 101”), safety and tolerability upon administering 2 mg/kg, 5 
mg/kg, 10 mg/kg and 15 mg/kg of E6011 were evaluated as primary objectives. Analysis of the 12-week 
administration has been completed, and there were no safety or tolerability problems concerning Crohn's 
disease with the 2 to 15 mg/kg repeated administration. In addition, exploratory evaluation of efficacy 
showed a trend towards improvement in the clinical symptoms of Crohn's disease. 
 Based on the above results and in view of the present demand for a Crohn's disease drug with a new 
mechanism of action in terms of efficacy and safety, a double-blind, placebo-controlled, parallel-group 
clinical trial has been designed to evaluate the efficacy and safety of E6011, which is a new drug expected 
to benefit Crohn's disease patients. Due to the number of Crohn's disease patients being smaller in Japan 
compared to Europe and America, making it difficult to enrol subjects in Japan alone, and due to the fact 
that the next phase of the clinical trial is going to be focused on non-Japanese patients, this clinical trial 
has been designed as a multinational clinical trial with added participation of European countries. 
 
8.  Clinical trial objective 
 To perform the following evaluation after administering E6011 to patients with moderate to severe 
active Crohn’s disease. 
 
8.1   Primary objective 
To examine the efficacy and safety of E6011 at 12 weeks after administration by means of double-blind 
placebo-controlled trial. 
 
8.2   Secondary objective 
·  To examine the efficacy and safety of a long-term administration of E6011. 
·  To evaluate the pharmacokinetics and immunogenicity of E6011. 
 
8.3   Exploratory objective 
 
 
 
CCI

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 25 of 80 
 
9.  Clinical trial plan 
9.1   General clinical trial design and plan 
 This is a multinational, multicentre, randomised, double-blind, placebo-controlled, parallel-group, 
early phase 2 clinical trial. This clinical trial consists of a screening period, remission-induction period 
(double blind), rescue period (open-label), extension period (open-label), post-observation period and 
follow-up period. Administration of the IMP is to start after confirming eligibility at baseline (at week 0 
before the start of the IMP administration) upon having carried out the screening test within 42 days prior 
to the start of the IMP administration after obtaining consent. 
 Patients with moderate to severe active Crohn’s disease are to be randomly allocated to an E6011 
10mg/kg group and a placebo group (1:1) using stratified allocation in which race (Japanese/non-Japanese) 
and history of previous use of biologics (yes/no) are used as allocation factors. The administration volume 
(about 100 mL) is to be prepared based on the weight of the subject by diluting E6011 with a physiological 
saline solution, and infused intravenously over approximately 30 minutes. The physiological saline 
solution used to dilute E6011 is to be used as a placebo. The remission-induction period is to last 12 weeks, 
with E6011 or placebo administered in a double-blind method on Week 0, Week 1, Week 2, and once 
every two subsequent weeks up to Week 10, and the efficacy of E6011 is to be evaluated in Week 12. 
Subjects with a reduction in the CDAI (Crohn’s Disease Activity Index) of 70 or more (responders) 
compared to baseline at evaluation on Week 12 are to move on to the open-label extension period. The 
extension period is to last 40 weeks, with 10 mg/kg of E6011 administered every four weeks from Week 
12 to Week 48 and E6011 efficacy is to be evaluated at Week 52. 
 Subjects with less than 70 reduction in the CDAI (non-responders) at evaluation in Week 12 are to 
move on to the rescue period. The rescue period is to last 12 weeks, with additional administrations of 10 
mg/kg of E6011 in Week 12, Week 13, Week 14 and every two subsequent weeks up to Week 22. Subjects 
with a reduction in the CDAI of 70 or more compared to baseline/Week 12 at evaluation in Week 24 of the 
rescue period are to move on to the open-label extension period. The extension period is to last 40 weeks, 
with 10 mg/kg of E6011 administered every four weeks from Week 24 to Week 60 and E6011 efficacy is to 
be evaluated at Week 64. Patients with less than 70 reduction in the CDAI compared to baseline and Week 
12 at evaluation in Week 24 are to be discontinued. 
 The Principal Investigator or Sub-investigator is to confirm that the subjects’ data as of Week 12 of the 
remission-induction period (double-blind) has been completely entered into the eCRF by the time the first 
evaluation in the rescue period or extension period takes place. Blinding in the double-blind period is to be 
maintained until a database in the double-blind study period is locked. 
 The post-observation period consists of an assessment in person 28 days after the completion or 
discontinuation of the extension period of the clinical trial, and an assessment in person or over the phone 
70 days after the last administration of the IMP. The follow-up period entails contacting the patients over 
the phone, etc. every 6 months until 2 years have passed from the last administration of the IMP to inquire 
whether they have experienced progressive multifocal leukoencephalopathy (PML). 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 26 of 80 
 
 Figure 1 shows the design of the clinical trial. 
Figure 1 Clinical trial design 
 
 
 
Responders at CDAI evaluation on Week 12 of the remission-induction period are to move on to the extension 
period, in which E6011 is administered every four weeks. Non-responders are to move on to the rescue period, and 
if the CDAI has improved by Week 24, they are to move on to the extension period, in which E6011 administered 
every four weeks. Subjects whose CDAI has not improved by Week 24 are to be discontinued. 
 
9.1.1   Screening period 
 After the clinical trial has been sufficiently explained to each subject, a written consent is to be 
obtained from each subject before carrying out any assessments and evaluations related to this clinical trial. 
Section5.3  describes procedures related to obtaining consent. 
 Patients who signed consent are to undergo screening period tests in between 42 days and one day 
before the start of the IMP administration. The Principal Investigator or Sub-investigator is to confirm 
whether each subject meets all inclusion criteria and does not fall under any of the exclusion criteria. 
 Screening results are to be recorded in the case report form. If a subject is deemed not eligible to 
participate in this clinical trial, the reason is to be recorded in the case report form. 
 Because subjects deemed to require prophylactic administrations of isoniazid as a result of tuberculosis 
check-up in the screening period will start receiving the IMP after more than 21 days of prophylactic 
administration, the screening period may be extended until 21 days have passed from starting isoniazid 
(Prophylactic treatment should be given in accordance with the local guidelines). 
 
9.1.2   Remission-induction period 
 Subjects who were deemed eligible to participate in the screening period and at baseline are to be 
allocated to the E6011 10 mg/kg group and placebo group at the ratio of 1:1 using stratified allocation in 
which race and history of previous use of biologics are used as allocation factors. E6011 or placebo is to be 
administered to allocated subjects in a double-blind method on Week 0, Week 1, Week 2, and every two 
subsequent weeks until Week 10. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 27 of 80 
 
 
9.1.3   Rescue period 
 Subjects with a reduction in the CDAI of less than 70 compared to baseline after finishing evaluation 
in Week 12 of the remission-induction period are to move on to the rescue period. The rescue period is to 
last 12 weeks, with 10 mg/kg of E6011 administered in an unblinded manner on Week 12, Week 13, Week 
14 and every two subsequent weeks until Week 22. 
 The Principal Investigator or Sub-investigator is to confirm before the first evaluation in the rescue 
period is carried out that non-responders’ data up to Week 12 of the remission-induction period 
(double-blind period) has been entered in the case report form. Blinding of each subject’s treatment group 
is to be maintained until the database of the remission-induction period is locked. 
 Subjects with a reduction in the CDAI of 70 or more compared to baseline or Week 12 at evaluation in 
Week 24 are to move on to the extension period. Subjects with less than 70 reduction in the CDAI 
compared to baseline and Week 12 are to be discontinued. 
 
9.1.4   Extension period 
 Subjects who finished evaluation at Week 12 of the remission-induction period and had a CDAI 
response of 70 or more, and subjects who moved on to the rescue period and finished evaluation at Week 
24 with a CDAI response of 70 or more are to move on to their respective extension period. The extension 
period is to last 40 weeks, with 10 mg/kg E6011 administered in an unblinded manner every four weeks up 
to Week 48 or Week 60. 
 The Principal Investigator or Sub-investigator is to confirm before the first evaluation in the extension 
period is carried out that responders’ data up to Week 12 of the remission-induction period (double-blind 
period) has been entered in the case report form. Blinding of each subject’s treatment group is to be 
maintained until the database of the remission-induction period is locked. 
 
9.1.5   Post-observation period 
 After the extension period of the clinical trial has been finished or discontinued, examinations are to be 
carried out 28 days after the completion or discontinuation of the extension period (in the hospital) and 70 
days after the last administration of the IMP (in the hospital or over a telephone call). 
 
9.1.6   Follow-up period 
 PML onset is to be investigated over the phone, etc. every 6 months in the two-year follow-up period 
after the last IMP administration. 
 
9.2   Discussion of the clinical trial design, including control group selection 
 This is a multinational, multicenter, randomised, double-blind, placebo-controlled, parallel-group, 
clinical trial with the primary objective of evaluating the efficacy and safety of E6011 in patients with 
moderate to severe active Crohn's disease. 
 In Japan’s Crohn’s disease treatment guidelines, oral adrenocorticosteroids (including budesonide), 
nutritional therapy and immunomodulators are used as remission-induction therapy in moderate to severe 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 28 of 80 
 
active Crohn's disease. Antibacterial drugs and apheresis are sometimes used as concomitant therapies. If 
oral adrenocorticosteroids and nutritional therapy are not effective, the use of anti-TNFα antibody 
biologics is recommended10. On the other hand, ECCO guidelines suggest using vedolizumab, an 
anti-α4β7 integrin antibody, as well as anti-TNFα antibody as biologics for the treatment of active Crohn's 
disease11. Recently, ustekinumab, an anti-IL-12/23 antibody, is beginning to be used as a drug indicated for 
Crohn's disease. As such, this clinical trial will be conducted to evaluate the efficacy of E6011 
administration in patients with moderate to severe active Crohn's disease who were not deriving 
satisfactory benefits from the use of existing drugs (adrenocorticosteroids, immunomodulative drugs, or 
biologics). 
 In this clinical trial, randomisation is to take place to eliminate bias in allocating subjects to treatment 
groups, to maintain balance in subject characteristics between the groups, and in order to improve validity 
of statistical comparison of the groups. Further, stratified allocation is to be performed in which race and 
history of biologic use, which might influence the efficacy evaluation, are used as allocation factors. In 
order to minimise the possibility of bias in data collection and endpoint evaluation, treatment groups are to 
be blinded. 
 EMA’s Guidelines on the development of new medicinal products for Crohn's disease state that “it is 
desirable that clinical symptoms in the active disease period improve within 12 weeks”. 12 As the results of 
Study 101 suggested that E6011 may be effective when administered for 12 weeks, evaluation period in 
the remission-induction period of this clinical trial was set to 12 weeks, with the primary endpoint as the 
ratio of subjects who had CDAI reductions of at least 100 points from basline at Week 12 (CR100 response 
rate). 
 Due to the fact that the subjects of this clinical trial were patients that did not derive sufficient benefits 
from treatment with existing drugs, an extension period of 40 weeks maximum was designed for subjects 
whose CDAI improve after the end of the 12-week remission-induction period (responders). A rescue 
period was also designed for subjects who do not show improvement in CDAI in the remission-induction 
period (non-responders) so that they would be able to receive E6011 in the same form and dosage as in the 
remission-induction period. The design is such that those subjects whose CDAI improve in the rescue 
period will move on to the extension period. It was decided that a design allowing both responders and 
non-responders to receive E6011 after the 12-week remission-induction period would be beneficial for the 
patients. 
 The post-observation period was set as 70 days after the last administration of the IMP, because of 
approximately five times the length of the longest observed half-life period of E6011. A follow-up period 
was designed to entail checking for the onset of PML, which is an anticipated risk of E6011, for two years 
after the last administration of the IMP. 
 
9.3   Selection of clinical trial population 
Approximately 40 subjects will be included in this clinical trial. 
 
E6011 group 20 subjects: Placebo group 20 subjects 
 
22 Japanese subjects: 18 Non-Japanese subjects (rough estimate) 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 29 of 80 
 
 
8 biologic-naive patients (rough estimate) 
 Subjects that meet all the following inclusion criteria and do not fall under any of the exclusion criteria 
shall receive the IMP. 
 
9.3.1   Inclusion criteria 
 Subjects who meet all the following criteria are eligible to participate in this clinical trial. 
(1) Crohn’s disease patients aged 18 or over and under 65 on the date of consent. 
(2) Patients diagnosed on basis of clinical findings, endoscopic findings, etc. with small intestine-type, 
small and large-intestine type, or large-intestine type Crohn's disease at least 12 weeks before giving 
consent. 
(3) Patients with a baseline (at Week 0 before the start of IMP administration) disease severity ranging 
from moderate to severe. CDAI score between 220 and 450, and a PRO2 score between 14 and 34. 
(4) Patients with a Simple Endoscopic Score for Crohn’s Disease (SES-CD) ≥7 (or for patients with 
isolated ileal disease, ≥4 in ileum segment) in the screening period, with one or more ulcers (in 
SES-CD score, ulcer presence subscore ≥ 1 in any segment) assessed by colonoscopy and confirmed 
by a centralised review. 
(5) Patients who received adrenocorticosteroids or immunomodulators in the past, but showed no 
therapeutic response (insufficient response) or the drugs were not tolerated (intolerance). 
Alternatively, patients who cannot taper adrenocorticosteroids (dependence). Alternatively, patients 
who showed no therapeutic response after administering biologic(s) (primary nonresponse), patients 
who initially showed therapeutic response but it lessened or disappeared afterwards (secondary 
nonresponse), or patients who did not tolerate the drug (intolerance). (Detailed criteria are described 
in Attachment 7 and Attachment 8). 
(6) If the patients are taking 1,200 kcal/day or less enteral nutrition, the dosage and administration have 
not changed for at least 4 weeks prior to the start of the IMP administration. 
(7) If the patients are taking aminosalicylic acid (5-ASA), salazosulfapyridine, or antibiotics for the 
treatment of Crohn's disease (metronidazole, ciprofloxacin, etc.), the dosage and administration have 
not changed for at least 4 weeks prior to the start of the IMP administration. 
(8) If the patients are taking under 30 mg/day of oral prednisolone (or equivalent adrenocorticosteroid) 
or 9 mg/day or less of oral budesonide, the dosage and administration have not changed for at least 4 
weeks prior to the start of the IMP administration. 
(9) If the patients are taking azathioprine (AZP), 6-mercaptopurine (6-MP) or methotrexate (MTX), the 
dosage and administration have not changed for at least 8 weeks prior to the start of the IMP 
administration. 
(10) Patients who have received a sufficient explanation about the compliance rules of this clinical trial, 
who are willing to comply with them, and who are able to do so. 
(11) Patients who voluntarily gave a written consent to participate in this clinical trial.  
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 30 of 80 
 
9.3.2   Exclusion criteria: 
 Patients who meet any of the following criteria shall be excluded from this clinical trial. 
(1) Patients diagnosed with ulcerative colitis or indeterminate colitis (refers to cases in which there is a 
difficulty distinguishing between Crohn’s disease and ulcerative colitis, intermediate colitis). 
(2) Patients diagnosed with gastrointestinal epithelial dysplasia. 
(3) Patients who have an abscess or are suspected to have one (however, patients with perianal abscess 
whose symptoms are stable with treatment, such as drug treatment or drainage, are not excluded). 
(4) Patients with an artificial anus, ileo-anal pouch or fistula (however, patients with anal fistula whose 
symptoms are stable with treatment, such as drug treatment or drainage, are not excluded). 
(5) Patients with symptomatic or high-grade gastrointestinal stenosis (patients who require expansion 
by endoscopy or who require have SES-CD score stenosis sub-score of 3, etc.). 
(6) Patients who, after undergoing small bowel resection, have been diagnosed with a short bowel 
syndrome, which makes maintaining caloric intake difficult. 
(7) Patients who have newly started seton drainage treatment within 12 weeks prior to the start of the 
IMP administration. 
(8) Patients who have undergone bowel resection or a gastrointestinal surgery within 24 weeks prior to 
the start of the IMP administration. 
(9) Patients who tested positive for C. difficile toxin test in the screening period. 
(10) Patients who tested positive for HIV, hepatitis B surface antigen (HBsAg), hepatitis B surface 
antibody (anti-HBs), hepatitis B core antibody (anti-HBc), hepatitis B virus DNA (HBV-DNA), 
hepatitis C virus antibody (anti-HCV), or human T cell leukemia virus type 1 antibody 
(anti-HTLV-1) in the screening period (however, this excludes patients who tested positive only for 
anti-HBs, clearly shown to be due to hepatitis B vaccination). Patients who tested negative for 
HBsAg and quantitative HBV-DNA and positive for anti-HBc antibody and/or anti-HBs antibody  
may participate in the clinical trial as long as the Principal Investigator or Sub-investigator takes 
proper measures such as monitoring HBV-DNA based on (not restricted to the following) 
• For Japan: Guidelines for measures against hepatitis B arising due to immunosuppression or 
chemotherapy 
• For Poland: Recommendations for the treatment of chronic viral hepatitis B in 2018 by Polish 
Group of Experts for HBV 
• For Hungary: Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus 
guideline 
• For Czech Republic: EASL (European Association for the Study of the Liver) 2017 Clinical 
Practice Guidelines on the management of hepatitis B virus infection 
• For Russian Federation: Order of Ministry of Health of Russian Federation #786н “On approval of 
the standard of specialized medical care for chronic viral hepatitis B" dd. 09.11.2012 
      In addition, patients who tested positive for HCV antibody and who were at least 24 weeks 
post-treatment may participate in the clinital trial as long as negative HCV-RNA is confirmed during 
the screening period. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 31 of 80 
 
(11) Patients with positive or repeated indeterminate (inconclusive) results on the TB test 
(QuantiFERON ® -TB Gold test or T-SPOT ® TB test). However, patients with indeterminate 
(inconclusive) results on repeated tests may be included in this clinical trial if they are started on 
prophylactic isoniazid least 21 days prior to the start of IMP administration. (The dose is generally 
300 mg/day. If the patient has a low body weight, the dose is to be 5 mg/kg a day. The drug is 
administered for approximately 9 months.) Prophylactic treatment should be given in accordance 
with the local guidelines. 
(12) Patients with findings showing a history of tuberculosis on a chest X-ray test in the screening 
period. 
(13) Patients with findings of neurological symptoms such as motor impairment, cognitive disorder, 
language disorder or dysphagia in the evaluations during the screening period. 
(14) Patients with a WBC count of less than 3,000/μL or blood CD4+ cell count under 200/μL in the 
screening period tests. 
(15) Patients with a medical history of clinically significant vasculitis. 
(16) Acute myocardial infarction, unstable angina pectoris, cerebral infarction, and symptomatic cerebral 
haemorrhage patients. 
(17) Patients whose AST or ALT was more than three times the upper normal limit in the screening 
period tests or patients whose serum creatinine level was more than 1.5 times the upper normal limit 
in the screening period tests. 
(18) Patients with a QTcF exceeding 450 ms repeatedly in standard 12-lead ECG tests in the screening 
period tests. 
(19) Patients who have undergone cytoapheresis (granulocytapheresis; GCAP) within 2 weeks prior to 
the start of the IMP administration. 
(20) Patients who required any one of the following treatments of infection; "hospitalization within 4 
weeks prior to the start of IMP administration", "intravenous treatment of antibiotics (including 
antiviral drugs) within 4 weeks prior to the start of IMP administration", or "oral treatment of 
antibiotics (including antiviral drugs) within 2 weeks prior to the start of IMP administration".  
 Furthermore, with regard to the novel coronavirus infection (COVID-19), patients who required any 
one of the following treatments; “hospitalization within 4 weeks prior to the start of IMP 
administration”, “any intravenous treatment within 4 weeks prior to the start of IMP administration” 
or “any oral treatment within 2 weeks prior to the start of IMP administration”.   
(21) Patients who received total parenteral nutrition (TPN), peripheral parenteral nutrition (PPN), or 
enteral nutrition exceeding 1200 kcal/day within 4 weeks prior to the start of the IMP administration. 
(22) Patients who received ≥30 mg/day of oral prednisolone (or an equivalent adrenocorticosteroid), 
adrenocorticosteroid injection, enema or suppository within 4 weeks prior to the start of the IMP 
administration. 
(23) Patients who received cyclosporine, mycophenolate mofetil, or tacrolimus within 8 weeks prior to 
the start of the IMP administration (excluding topical use). 
(24) Patients who received adalimumab, infliximab, certolizumab pegol, vedolizumab or ustekinumab 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 32 of 80 
 
(including biosimilars) within 8 weeks prior to the start of the IMP administration. 
(25) Patients vaccinated with live vaccines within 12 weeks prior to the start of the IMP administration 
or patients who received a vaccine that is considered to have a risk of infection, such as a virus vector 
vaccine that uses a virus that retains its ability to proliferatewithin 12 weeks prior to the start of the 
IMP administration 
(26) Patients who received an immunoglobulin preparation or a blood product within 24 weeks prior to 
the start of the IMP administration. 
(27) Patients who have received natalizumab or E6011 in the past. 
(28) Patients with a history of a malignant tumour, lymphoma, leukemia, or lymphoproliferative 
disorders, or with complications thereof. However, this does not include completely resected skin 
cancers (epithelial cell cancers or basal cell cancers) and cervical cancers with no metastasis or 
recurrence observed for 5 more years at the time of giving consent. 
(29) Patients with immunodeficiency or a history of HIV infection. 
(30) Patients with a history of severe allergy (shock, anaphylaxis-like symptoms). 
(31) Patients currently taking part in another clinical trial (including the post-observation period), or 
patients who were participating in another trial using an IMP or investigational medical device within 
28 days (or within five times the length of the half-life period of the IMP, whichever is longer) prior 
to giving consent. 
(32) Patients who received a faecal microbiota transplant (FMT), mesenchymal stem cell, etc. within 24 
weeks prior to giving consent. 
(33) Female patients of childbearing potential who had a positive result on the pregnancy test at 
screening or baseline, as well as lactating patients. 
(34) Female patients of childbearing potential who: 
• 
have not been on a highly effective method of contraception within 28 days prior to the start of 
IMP administration. The following are highly effective contraception methods: 
– 
Sexual abstinence (if preferred by subjects as their regular lifestyle) 
– 
Use of intrauterine device (IUD)  
– 
Contraceptive implant 
– 
Use of oral contraceptives 
– 
(The same oral contraceptive is to be used at a set dose for more than 28 days prior to the start of 
the IMP administration, and continued throughout the clinical trial and for 70 days after the last 
administration of the IMP) 
– 
The male partner has undergone vasectomy and azoospermia has been confirmed. 
• 
Patients who do not agree to continue using one of the highly effective contraception methods 
described above throughout the clinical trial and for 70 days after the last administration of the 
IMP 
• 
If the use of the aforementioned contraception methods is not appropriate or not allowed, the 
patients are required to consent to use another medically appropriate contraception method, i.e. a 
double-barrier method (combined use of a condom and contraceptive diaphragm, or a 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 33 of 80 
 
spermicide-containing cervical/vault cap, etc.) 
• 
All females are deemed to have childbearing potential. However, postmenopausal women 
(menopausal age patients who have not menstruated for at least 12 consecutive months, which has 
been confirmed not to be due to other factors, or is not suspected to be due to other factors) and 
women who have undergone surgical sterilization (patients who have undergone bilateral tubal 
ligation, hysterectomy, or bilateral oophorectomy more than one month prior to the IMP 
administration) are excluded from this rule. 
(35) Potential male patients with female partners of childbearing potential: 
• 
that have not undergone proper vasectomy (azoospermia can not be confirmed) who (or whose 
partners) do not agree to use contraception employing one of the methods listed in the exclusion 
criteria (34) during the clinical trial and for 70 days after the last administration of the IMP 
(however, if the female partner does is not of childbearing potential, the subject can participate in 
the trial) 
• 
patients whose female partner is pregnant and do not agree to use latex or synthetic condoms 
during the clinical trial and for 70 days after the last administration of the IMP 
• 
The patients must not donate sperm during the clinical trial and for 70 days after the last 
administration of the IMP 
(36) Patients who were judged to be unsuitable for participation in this clinical trial by the Principal 
Investigator or Sub-investigator. 
 
9.3.3   Termination of subject treatment or evaluation 
 The Principal Investigator or Sub-investigator may terminate the subjects’ participation in the clinical 
trial at any time for safety reasons or reasons related to the conduct of the clinical trial. The subjects 
themselves may request discontinuation of the IMP administration or participation in the clinical trial at 
any time without providing explanation. 
 All subjects who discontinue the clinical trial after the start of the IMP administration are to undergo 
assessments at discontinuation outlined in the study schedule (Table 4) (see “9.5.5   Subject completion 
and withdrawal ”). 
 Note that if any of the following applies to the subject, he or she is to be discontinued. 
(1) The subject has experienced adverse events which make continuation difficult. 
(2) The subject’s pregnancy has been confirmed. 
(3) The subject has been deemed to be ineligible to participate in the clinical trial. 
(4) It has become difficult for the subject to continue to use a concomitant drug/concomitant therapy as 
instructed. 
(5) The subject requires a surgical operation. 
(6) The subject has been diagnosed with gastrointestinal epithelial dysplasia. 
(7) The subject has been diagnosed with a malignant tumour. 
(8) The subject has less than 70 reduction in the CDAI at Week 24 (rescue period) compared to baseline 
and Week 12. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 34 of 80 
 
 
9.4   Treatment method 
9.4.1   IMP administration method 
 The dose of E6011 corresponding to the subject’s weight is to be diluted with a physiological saline 
solution to prepare a 10 mg/kg E6011 dosing solution (approximately 100 mL). The physiological saline 
solution used to dilute E6011 is to be used as a placebo. The weight measurements used in the 
weight-dosage conversion to establish dosage (full dose) are to be the measurements taken on Week 0, 
Week 12, Week 24, Week 36 and Week 48 (only subjects moving on the rescue period), and the conversion 
dosage (full dose) may not change even if the patient gains or loses weight in between the measurements. 
IMP preparation procedure details are listed in Attachment 4. 
 The IMP is to be infused intravenously through an in-line filter (pore size: 0.2 μm) using an infusion 
pump over approximately 30 minutes (including saline flush). If drug hypersensitivity thought to be related 
to the IMP administration is observed, the subsequent infusion rate can be reduced, and the patient may be 
prophylactically premedicated with antihistamines and antipyretics. 
 The IMP is to be administered after all investigations scheduled for that day, excluding 
post-administration blood collection for the purpose of measuring serum E6011 concentration, have been 
completed. 
 The subject is to stay in the hospital for 60 minutes after the first and second administration in the 
remission-induction period and the rescue period, and is allowed to leave after safety has been confirmed. 
 
 The IMP is to be administered in the following periods (Table 1). 
• 
Remission-induction period: E6011 or placebo is to be administered with repeat IV dosing to the 
E6011 10 mg/kg group or placebo group in Week 0, Week 1, Week 2, and every 2 subsequent 
weeks until Week 10. 
• 
Rescue period: 10 mg/kg of E6011 is to be administered with repeat IV dosing in Week 12, Week 
13, Week 14, and every 2 subsequent weeks until Week 22. 
• 
Extension period: 10 mg/kg of E6011 is to be administered with repeat IV dosing every 4 weeks 
from Week 12 to Week 48 to remission-induction period responders, and from Week 24 to Week 
60 after the completion of the rescue period to remission-induction period non-responders. 
 
Table 1 IMP administration method 
 IMP  
 Dosage  
 Dosage 
form  
 Administration method  
 Administration period  
 E6011  
 10 mg/kg  Aqueous 
solution  
 10 
mg/kg 
of 
E6011 
dosing 
solution (approximately 100 mL) is 
to be infused intravenously over the 
period 
of 
approximately 
30 
minutes.  
 Remission-induction 
period: 12 weeks 
 Rescue period: 12 weeks 
 Extension period: 40 
weeks  
 Placebo  
 N/A  
Aqueous 
solution  
 The physiological saline solution 
(approximately 100 mL) is to be 
infused intravenously over the 
period 
of 
approximately 
30 
 Remission-induction 
period: 12 weeks 
 Rescue period: No 
administration 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 35 of 80 
 
minutes.  
 Extension period: No 
administration  
 N/A: Not applicable 
 
 The Principal Investigator shall appoint the Clinical Trial Centre’s pharmacist or a person with 
appropriate qualifications as the unblinded trial staff (unblinded trial pharmacist, unblinded trial doctor, or 
unblinded trial coordinator). Until maintaining the blinding is no longer necessary, such as at code break, 
only the unblinded trial pharmacist or unblinded trial doctor can prepare the IMP. The unblinded trial 
pharmacist or unblinded trial doctor, upon confirming the subject’s allocation group and the subject’s 
weight, is to prepare an E6011 dosing solution. The unblinded trial pharmacist or unblinded trial doctor is 
to create an IMP preparation record and deliver prepared IMP to the IMP administration trial staff, 
maintaining the blinding. Only an IMP administration trial staff who has undergone a proper training can 
administer the IMP. In the double-blind period, the unblinded trial pharmacist or unblinded trial doctor is 
to dispense the IMP after placing a semi-transparent or non-transparent concealing cover on the 
intravenous drip bottle sealed using a sticker, and after the IMP administration has been completed, the 
unblinded trial staff is to confirm that the seal sticker is still intact indicating that the concealing cover has 
not been taken off from the bottle until the end of administration, and that the blinding is thus maintained. 
 
9.4.2   IMP identification 
 The IMP used in this clinical trial is shown in Table 2. 
 E6011 is to be stored in a labelled, dedicated box and supplied by the Sponsor. Each box is to contain 10 
vials of E6011. Details concerning the IMP label and packaging are listed in Attachment 5. 
 
Table 2 IMP 
 Type  
 Dosage form and content  
 Manufacturer  
 E6011  
 Aqueous solution containing 100 mg of E6011 in 1 
vial (1 mL)  
 Eisai Co., Ltd.  
 
9.4.2.1   E6011 chemical name, structural formula, etc. 
• 
Test drug code: E6011 
• 
Generic name: Undetermined 
• 
Chemical name: IgG2 
• 
Molecular weight: 147kDa 
• 
Structural formula: Glycoprotein of an immunoglobulin structure comprising two light chains 
each consisting of 214 amino acid residues and two heavy chains each consisting of 445 amino 
acid residues connected by a disulfide bond 
 
9.4.2.2   Control drug 
 Placebo 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 36 of 80 
 
9.4.2.3   IMP label 
 E6011 label is to follow applicable regulations of the participating countries and be written in the 
languages required by each of the participating countries. 
 Details concerning the IMP label and packaging are listed in Attachment 5. 
 
9.4.2.4   Storage conditions 
 The IMP is to be stored according to prescribed storage conditions. The trial pharmacist (or his/her 
representative) shall monitor the temperature of the storage location and make sure that the IMP is being 
stored at the prescribed temperature range. The Principal Investigator (or his/her representative) (or, in 
accordance with the regulations of each region, the head of Clinical Trial Centre) shall be responsible for 
ensuring that the storage location temperature is being monitored throughout the period of the clinical trial, 
and that the records thereof are being stored. When recording temperatures, a temperature data collection 
system and automatic temperature recording devices validated at each respective Clinical Trial Centre, 
handwriting, or other methods are to be used. Further, it is required that the monitoring method enable to 
check the lowest and highest temperature recorded and managed over a given period if necessary. 
 
9.4.3   Method of allocating subjects to treatment groups 
A screening test is to take place within 42 days prior to the start on IMP administration, and patients 
whose eligibility has been confirmed are to be allocated to the E6011 10 mg/kg group or placebo group at 
a ratio of 1:1 using stratified allocation in which race and history of previous use of biologic medications 
are used as allocation factors. 
 Randomisation is to be performed by a central allocation method using an Interactive Web Response 
System (IWRS). At Week 0, the Principal Investigator (or his/her representative) is to enter the subjects’ 
information into the IWRS. After subject registration is complete in the IWRS, the confirmation of 
registration (not including the information on group allocation) are to be notified via an e-mail to the 
Principal Investigator (or his/her representative), unblinded staff and Sponsor. Access to IWRS is to be 
restricted so that information on group allocation can be only retrieved by the unblinded trial staff of the 
Clinical Trial Centre and the unblinded trial staff of the Sponsor. The Principal Investigator or 
Sub-investigator is to record the eligibility results in the screening log/enrolment log, and prescribe the 
IMP to subjects deemed eligible to participate at screening and baseline evaluation. 
 After confirming the prescription by the Principal Investigator or Sub-investigator, the unblinded trial 
staff is to validate the registration results and allocation groups in the IWRS, and the unblinded trial 
pharmacist or unblinded trial doctor is to prepare the IMP in accordance with the treatment group 
allotment indicated by IWRS. 
 
9.4.4   Dosage selection in the clinical trial 
 In the 12-week period administration in Study 101, adverse events have been observed in 18 out of 28 
subjects (64.3%). Of out these, adverse events observed in 2 or more subjects included nasopharingitis in 5 
subjects (17.9%), and headache, nausea, anal abscess, and Crohn’s disease in 2 subjects each (7.1%). 
Increase of E6011 dose-dependent incidence of side-effects and any concerning events were not observed, 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 37 of 80 
 
and there were no safety or tolerability issues for Crohn’s disease patients with the dosage range up to 15 
mg/kg of IV E6011 administered biweekly. Concerning efficacy, although Study 101 is an open-label trial 
designed not to include a placebo group, evaluations up to Week 12 showed a trend towards improvement 
of clinical symptoms of Crohn’s disease in each group (E6011 2 mg/kg group, 5 mg/kg group, 10 mg/kg 
group and 15 mg/kg group). Highest numbers of patients with improvement and patients who achieved 
remission were in the 10 mg/kg group. 
 By means of PK/PD analysis which used serum E6011 concentration and serum total FKN (the sum of 
free FKN and E6011-FKN complex) concentration in Study 001 and Study 002, a simulation of 
connectivity between E6011 used in Study 101 and its target, membrane-bound FKN, has been performed. 
Analysis showed that E6011 occupancy on membrane-bound FKN was approximately 99% with 10 
mg/kg. 
 The above results showing that sufficient target occupancy and clinical symptom improvement can be 
expected with 10 mg/kg, it has been judged that in this clinical trial, which is a pivotal POC study, 10 
mg/kg is the appropriate dosage to evaluate the efficacy of E6011 remission-induction. As in Study 101, 
dosing was set to take place in Week 0, Week 1, Week 2, and every 2 subsequent weeks. 
 As for the dosage and administration in the extension period, considering the fact that the subjects are 
patients who had experienced an improvement of their symptoms, as well as for subject convenience, 10 
mg/kg, a dosage identical to the one used in the remission-induction period, was chosen to be administered 
intermittently at 4 week intervals. 
 
9.4.5   Dosage selection for each subject and administration period 
 See section 9.4.1 IMP administration method.  
 The IMP can be administered regardless of meals. 
 The IMP is to be administered after completing all assesssments scheduled for that day (excluding 
blood sampling immediately after the end of administration to measure serum E6011 concentration). 
 
9.4.6   Blinding 
 During the double-blind period, information on treatment groups must not be disclosed to subjects or 
any blinding staff involved in implementation and evaluation of the clinical trial. The randomised data is to 
be strictly controlled, and the Sponsor or CRO is to store it carefully. Further, until code break, the data 
must not be known to anyone besides the persons designated in the procedure manual. 
Although the rescue period and extension period are open-label trials, the information on each subject’s 
treatment group must not be disclosed to subjects or any blinding staff until the remission-induction period 
database is locked. 
 After code break, the institution measuring drug concentration and the institution measuring 
immunogenicity are to report each subject’s measurement result to the Sponsor. 
 The colonoscopy image is to be sent to an imaging assessment professional, where it is to be evaluated 
in a blinded manner to maintain subject blinding.  
 The IMP supplier, IWRS and the Sponsor are to store the coding key listing treatment groups 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 38 of 80 
 
corresponding to subject numbers in a sealed condition. When it is deemed necessary to learn about the 
IMP treatment group in case of medical emergencies, the data might be unblinded by following the IWRS 
code break procedure. Section9.5.4.5  describes the unblinding procedure. The Investigators are to, as 
soon as possible prior to code break, confirm with the Sponsor the necessity thereof. 
 
9.4.6.1   Blinding method 
Blinding is to be maintained for the subjects and the blinded staff in the following way. 
 ・A physiological saline solution is to be used as control for the IMP. 
 ・Blinding maintenance systems are to be put in place both at the Sponsor’s and at the Clinical Trial 
Centre. Unblinded staff are to be designated on the task delegation log before the start of the clinical 
trial. 
 ・Until it is no longer necessary to maintain blinding, such as at code break, the Sponsor’s unblinded 
trial monitor is to be the person contacting the unblinded trial staff about the delivery (however, this 
excludes first delivery) in order to maintain blinding by not using any blinded staff as an intermediary. 
 ・Until it is no longer necessary to maintain blinding, such as at code break, only the unblinded trial 
pharmacist or unblinded trial doctor can prepare the IMP. The unblinded trial pharmacist or unblinded 
trial doctor is to prepare the IMP in an environment closed off from blinded staff. 
 ・The unblinded trial pharmacist or unblinded trial doctor is to create an IMP preparation record, and 
deliver the prepared IMP to the IMP administration staff while maintaining the blinding (the IMP used 
in the double-blind period is dispensed with a translucent concealing cover placed on the intravenous 
drip bottle). 
 ・After the end of the IMP administration, the unblinded trial staff is to confirm that the concealing 
cover has not been taken off from the bottle until the end of administration, and that the blinding is 
thus maintained. 
 
9.4.6.2   Maintenance of blinding 
An emergency key is to be created by inserting the allocation number table into the subject registration 
system, and the key is to be stored by IWRS. Note that the emergency key cannot not be opened other than 
by a procedure determined in advance. (See section 9.5.4.5 ) 
 
9.4.6.3   Reporting blinded item measurement results 
 In order to maintain blinding, results of the following laboratory tests are to be stored at each 
measuring institution until code break, and they may not be disclosed to the Principal Investigator, 
Sub-investigator, trial coordinator and Sponsor. If the Sponsor needs to obtain the laboratory test results 
before code break, the obtained information must be limited to a necessary minimum, and each measuring 
institution must re-blind subject information and submit a measurement report as means of maintaining the 
blinding of each subject. 
 - Serum E6011 concentration 
 - Serum anti-E6011 antibodies 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 39 of 80 
 
 - Serum total FKN concentration 
 - Blood CD16+ monocytes, etc. (only collected by Japanese subjects) 
 - Blood CD16+ monocytes, etc. genetic marker 
 - To explore blood biomarkers (comprehensive proteome analysis) using the residual serum collected 
for this study 
 
9.4.7   Prior treatment and concomitant treatment 
 Prior treatment and concomitant drugs/treatment are to be as specified below.All drugs (including 
over-the-counter products) and concomitant therapies used from the time of obtaining consent to the end 
(or discontinuation) of the extension period are to be recorded in the case report form. If the Principal 
Investigator or Sub-investigator used any concomitant drugs and therapies as measures against adverse 
events, he is to record them in the case report form. Vaccines administered during the clinical trial are to be 
recorded in the case report form as concomitant therapies (concomitant use of live vaccinesand vaccines 
that are considered to be at risk of infection, such as  virus vector vaccines using viruses that retain the 
ability to proliferate, are prohibited). 
 Drug name, administration route, administered amount, date of starting the administration, date of 
ending the administration, and reason for use are to be recorded in the case report form for all drugs. 
However, health foods such as vitamins, injection solutions, and drugs used in examinations and diagnostic 
imaging do not need to be recorded in the case report form. 
 If concomitant drugs and therapies were used for the treatment of subjects’ medical symptoms 
observed at obtaining consent, the symptoms are to be recorded in the case report form as disease 
complications. 
 
9.4.7.1   Prohibited concomitant therapies and concomitant drugs 
9.4.7.1.1   Prohibited concomitant therapies and concomitant drugs 
 The concomitant use of the following drugs/treatments shall be prohibited until the end of the 
extension period (or discontinuation). 
• 
Biologics (infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab and 
natalizumab, including biosimilars) 
• 
Adrenocorticosteroid injections, enemas and suppositories 
• 
Cyclosporine, mycophenolate mofetil, tacrolimus (excluding topical use) 
• 
Immunoglobulin preparations, blood products 
• 
Cytoapheresis (GCAP) 
• 
Total parenteral nutrition (TPN), peripheral parenteral nutrition (PPN) 
• 
Faecal microbiota transplant, mesenchymal stem cell, etc. 
• 
Live vaccine  
• 
Vaccine with possible risk of infection such as virus vector vaccine using virus having 
proliferation capability 
• 
Other IMPs/investigational medical devices 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 40 of 80 
 
Attachment 6 shows a detailed list of prohibited concomitant drugs. 
 
9.4.7.1.2   Restricted concomitant drugs 
 The following drugs may be used in combination with the IMP, but the dosage and administration may 
not be changed until Week 12 (or until discontinuation). 
 In principle, the dosage and administration may not be changed from Week 12 until the end of the 
extension period, but dosage reduction, discontinuation, increasing dosage after dosage reduction (up to 
the dosage used at the start of the IMP administration) or resuming administration after discontinuation is 
allowed. If the symptoms of subjects taking oral adrenocorticosteroids or receiving oral budesonide 
improve (CR100 achievement), the dosage is to be reduced in principle, using as reference the steroid 
dosage reduction schedule set forth in Attachment 9. 
• 
Aminosalicylic acid (5-ASA) 
• 
Salazosulfapyridine 
• 
Antibiotic drugs for the treatment of Crohn’s disease 
• 
Oral administration of adrenocorticosteroids (less than 30 mg/day of prednisolone equivalent), 
oral budesonide (9 mg/day or less) 
• 
Azathioprine (AZP) 
• 
Mercaptopurine (6-MP) 
• 
Methotrexate (MTX) 
• 
Enteral nutrient preparation (1,200 kcal/day or less) 
The SARS-CoV-2 vaccine may be used concomitantly, but it should not be administered within 7 days 
before or after the IMP administration. 
Attachment 6 shows a detailed list of restricted concomitant drugs. 
 
9.4.7.1.3   Restricted concomitant therapies 
 Seton drainage treatment may be concomitantly used with the IMP, but new seton placement is 
prohibited from 12 weeks prior to the start of IMP administration until the end of the extension period (or 
discontinuation). 
 
9.4.8   Compliance with the treatment method 
 The Principal Investigator, Sub-investigator or trial coordinator is to record the date of the IMP 
administration, time of the start of administration, time of the end of administration, and administration 
conditions in the case report form. If the full dose of the IMP could not be administered, the reason thereof 
is to be recorded in the case report form. The monitor is to monitor the administration compliance status 
when visiting the Clinical Trial Centre. 
 Until it is no longer necessary to maintain blinding, such as at code break, the unblinded trial monitor 
is to check whether the IMP dosage is prepared correctly in each allocation group, and whether the IMP is 
being administered to the subjects, and record his/her observations at Clinical Trial Centre visits. 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 41 of 80 
 
9.4.9   Supply and management of IMP 
 The Principal Investigator (or, in accordance with the regulations of each region, the head of Clinical 
Trial Centre, or his/her designated trial pharmacist or representative) is responsible for handling the IMP 
(use, storage, maintaining records) in accordance with the IMP handling procedure manual received from 
the Sponsor, GCP, local regulations or the regulations of each region. 
 Blinding maintenance systems are to be put in place both at the Sponsor’s and at the Clinical Trial 
Centre in order to handle blinded information in the IMP delivery work in this clinical trial. The Principal 
Investigator (or, in accordance with the regulations of each region, the head of Clinical Trial Centre, or 
his/her designated trial pharmacist or representative) is to appoint a pharmacist or other qualified person of 
the Clinical Trial Centre as an unblinded trial staff that is different from the blinded staff. For the purpose 
of maintaining blinding at the Clinical Trial Centre, the Sponsor is to convey appropriate information to 
the unblinded trial staff of the Clinical Trial Centre and educate and instruct them how to store the IMP. 
Blinding maintenance system is to continue operating after the earliest possible first delivery of the IMP 
until it is no longer necessary to maintain blinding, such as at code break. For details, see “Blinded data in 
E6011-ET2 handling manual”. 
 The Sponsor is to deliver the IMP to the trial pharmacist upon conclusion of the clinical trial agreement 
between the Clinical Trial Centre and the Sponsor.  
The Principal Investigator shall not use the IMP for purposes other than the conduct of this clinical trial. 
The Principal Investigator is also not allowed to provide the IMP to individuals who are not participating 
in this clinical trial. 
 The Clinical Trial Centre is to accurately record the quantity of received IMP, number of prescribed 
IMP, number of IMP prescribed but not administered to subjects (unused IMP-1), number of IMP that the 
Clinical Trial Centre received but not prescribed to subjects (unused IMP-2) and number of IMP returned 
to a storage warehouse designated by the Sponsor (sum of unused IMP-1 and unused IMP-2) (if any 
quantities of IMP were disposed of at the Clinical Trial Centre, this is also to be recorded). The data to be 
recorded includes, but is not limited to the following examples: (a) record of IMP recipient, (b) log of 
prescribed and returned IMP per subject, (c) IMP management log, (d) set of documents enclosed at IMP 
delivery, (e) record of IMP return, (f) if the IMP was disposed of at the Clinical Trial Centre, the record 
thereof. The Sponsor shall provide all the above forms. If the Clinical Trial Centre wishes to use other 
forms, it has to obtain permission of the Sponsor. 
 IMP management records must be viewable upon request when the monitor is carrying out 
investigation (if the investigation takes place before code break, the unblinded monitor is to be in charge) 
or when a regulatory authority personnel is performing an inspection. If the Sponsor has not defined rules 
of disposing of the IMP at the Clinical Trial Centre, the Principal Investigator (or, in accordance with the 
regulations of each region, the head of Clinical Trial Centre, or his/her designated trial pharmacist or 
representative) is to, during the clinical trial or after its completion, return all unused IMP (including 
empty boxes and unused IMP-2) to a storage warehouse designated by the Sponsor. The IMP may be 
disposed of at the Clinical Trial Centre only if, due to regulations or special circumstances surrounding the 
IMP used in this clinical trial, it is impossible to return the IMPs to a storage warehouse designated by the 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 42 of 80 
 
Sponsor. When disposing of the IMP at the Clinical Trial Centre, it is necessary to obtain the Sponsor’s 
permission before starting the disposal procedure. The trial pharmacist (or his/her representative) is to 
confirm the number of all unused IMP and after exchanging with the Sponsor a collection statement and 
return statement, return the IMP to a storage warehouse designated by the Sponsor. The IMP must be 
packaged in accordance with the regulations of each region and sent back to a storage warehouse 
designated by the Sponsor. Depending on the region, the IMP to be returned by the Clinical Trial Centre 
may be directly collected by the monitor, who will then deliver them to a storage warehouse designated by 
the Sponsor (if the IMP is collected before code break, the unblinded monitor is to be in charge). If the 
Sponsor has given permission to dispose of the IMP at the Clinical Trial Centre, the disposal is to follow 
the procedure stipulated by the Clinical Trial Centre, and a record thereof is to be submitted to the Sponsor. 
 The monitor is to monitor the IMP use status throughout the period of the clinical trial at Clinical Trial 
Centre visits, at the end of the clinical trial, etc. 
 
9.5   Clinical trial methodology 
9.5.1   Assessment items 
 The Principal Investigators, Sub-investigators or trial coordinator shall assess the following items in 
subjects who have given consent and record them in case report forms. 
 
9.5.1.1   Demographic characteristics and assessment method 
 Each subject’s demographic characteristics are to be assessed at the time of screening. Items include 
date of birth, sex, race and ethnicity. In addition to these items, the subject ID Code and the date of consent 
are also to be recorded in their case report form. 
 
9.5.1.2   Assessment items and method during the screening period 
9.5.1.2.1   History of Crohn's disease 
 To be assessed and recorded in case report forms during the screening period: Crohn’s disease-related 
surgery, disease type (small intestine-type, small and large intestine-type, or large intestine-type), affected site 
(e.g., anus/perianus, rectum, duodenum, colon, jejunum, ileum), and the time of onset. 
 
9.5.1.2.2   Prior treatment 
 Information to be recorded in case report forms regarding prior biologic treatment of Crohn's disease: 
drug name, route of administration, dosage, treatment start date (treatment start period), treatment end date, 
reason for the discontinuation, etc. 
 
9.5.1.2.3   Past medical history/complications 
 To be assessed during the screening period: past medical history (including surgery unrelated to 
Crohn's disease) and complications (including intestinal and extraintestinal complications of Crohn's 
disease). Complications and past medical history (within 5 years prior to the time of giving consent) that 
the Principal Investigators or Sub-investigators judge to affect efficacy or safety are to be recorded in case 
report forms. Conditions that are ongoing at the time of consent but have resolved before IMP 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 43 of 80 
 
administration (e.g., cold) are treated as complications. 
 
9.5.1.2.4   Other items assessed during the screening period in this clinical trial or 
specific to the disease area 
 < C. difficile toxin test> 
 Subjects’ stool samples are collected during the screening period and tested for C. difficile toxins. 
Assays are done at a lab facility and test results are recorded in the medical record of clinical trial centres. 
Samples are to be handled according to the procedures outlined separately. 
 
 <Viral test, tuberculosis test> 
 A viral test (for HIV, HBsAg, anti-HBs, anti-HBc, HBV-DNA, anti-HCV (and HCV-RNA as needed 
for anti-HCV positive patient), and anti-HTLV-1) and tuberculosis test (QuantiFERON ® -TB Gold or 
T-SPOT ® .TB test) are to be conducted. Assays are done at a lab facility (except for the QuantiFERON ® 
-TB Gold test and the T-SPOT ® .TB test if it is carried out at clinical trial centres) and test results are 
treated as source data at clinical trial centres. Samples are to be handled according to the procedures 
outlined separately. 
 
<Chest X-ray test> 
Chest X-ray tests in two directions of transverse and side views are conducted and the results of 
normal/abnormal assessment are to be recorded in case report forms. Additionally, if symptoms suggestive 
of tuberculosis are observed after the start of the IMP administration, examinations such as a chest X-ray 
should be performed to check for tuberculosis at the discretion of the Principal investigator or 
Sub-investigators. 
 
 
9.5.1.3   Assessment items and method for efficacy evaluations 
9.5.1.3.1   Evaluation of disease activity based on CDAI score and PRO2 
 <CDAI> 
 CDAI is to be calculated when indicated by the study schedule (Table 4). 
 Among the CDAI evaluations, the number of liquid or very soft stools and scores for abdominal pain 
and general well-being are evaluated by subjects themselves using the electronic patient reported outcomes 
and entered electronically. 
 The Principal Investigators, Sub-investigators or clinical trial coordinators shall contact the subjects the 
day before the start of a weekly evaluation to ensure that they properly enter the number of liquid or very 
soft stools and scores for abdominal pain and general well-being. 
The Principal Investigators or Sub-investigators are to evaluate each subject’s disease state and use, 
among others, the electronic patient reported outcomes and pertinent test results to evaluate the CDAI 
(Attachment 10). As a general rule, the CDAI evaluations should be performed by the same Principal 
Investigator or Sub-investigator at each clinical trial centre. Principal Investigators, Sub-investigators or 
trial coordinators shall record the results of CDAI evaluations in case report forms. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 44 of 80 
 
 Evaluation day haematocrit (within the visit window) and weight values, and screening period height 
value should be used to calculate the CDAI. To eliminate the effect of colonoscopy on CDAI evaluations, 
the results from the most recent week, excluding the day before, the day of, and the day after colonoscopy 
should be used for electronic patient reported outcomes. 
 If any of the number of liquid or very soft stools and scores for abdominal pain and general well-being 
is missing for one day, the mean number of liquid or very soft stools over the other six days (rounded to 
the nearest integer) and the maximum abdominal pain and general status scores in the other six days are to 
be used as substitutes. 
If any of the number of liquid or very soft stools and scores for abdominal pain and general well-being 
is missing for two days, the mean number of liquid or very soft stools over the other five days (rounded to 
the nearest integer) and the maximum abdominal pain and general status scores in the other five days are 
to be used substitutes. If information from three or more days is missing, it is treated as missing and CDAI 
is not calculated. 
 In the evaluation of disease activity level based on CDAI scores, CR70 and CR100 are defined as 
clinical response with a decrease of ≥ 70 points and ≥ 100 points from baseline, respectively, and 
remission is defined as CDAI < 150. 
 
<PRO2> 
 PRO2 is to be calculated when indicated by the study schedule (Table 4). 
 In PRO2 evaluations, the number of liquid or very soft stools and abdominal pain score are evaluated 
by subjects themselves using the electronic patient reported outcomes and entered electronically. 
 The Principal Investigators, Sub-investigators or clinical trial coordinators shall contact the subjects the 
day before the start of a weekly evaluation to ensure that they properly enter the number of liquid or very 
soft stools and scores for abdominal pain and general well-being. 
 Principal investigators or sub-investigators are to evaluate PRO2 based on the electronic data on 
electronic patient reported outcomes (Attachment 11). 
 To eliminate the effect of colonoscopy test on PRO2 evaluations, the results from the most recent week, 
excluding the day before, the day of, and the day after colonoscopy should be used for electronic patient 
reported outcomes. 
 If any of the number of liquid or very soft stools and abdominal pain score is missing for one day, the 
mean number of liquid or very soft stools over the other six days (rounded to the nearest integer) and the 
maximum abdominal pain score in the other six days are to be used substitutes. If any of the number of 
liquid or very soft stools and abdominal pain score is missing for two days, the mean number of liquid or 
very soft stools over the other five days (rounded to the nearest integer) and the maximum abdominal pain 
score in the other five days are to be used as substitutes. If information from three or more days is missing, 
it is treated as missing and PRO2 is not calculated. 
In the evaluation of disease activity level based on PRO2, PRO2-CR5 (equivalent to CR70) and 
PRO2-CR8 (equivalent to CR100) are defined as clinical response with a decrease of 5 or more points 
from baseline, and 8 or more points from baseline, respectively, and PRO2-remission is defined as PRO2 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 45 of 80 
 
less than 8 points. 13  
With regards to electronic patient information outcomes, to prevent influencing self-evaluations, 
subjects are to perform their evaluations prior to all tests/evaluations in the applicable evaluation period 
conducted by Principal Investigators or Sub-investigators, except at the time of discontinuation. To ensure 
accuracy and completeness of subject entries, if data entered the previous day is incomplete, Principal 
Investigators, Sub-investigators or trial coordinators are to contact the subject and instruct him/her to enter 
the missing data before the end of the day. These evaluations are made at each evaluation point and will 
not be compared to the past evaluations. 
 
9.5.1.3.2   Endoscopic evaluation of GI disorder by SES-CD 
 Endoscopy is to be performed and the SES-CD score calculated when indicated by the study schedule 
(Table 4). 
 Principal Investigators or Sub-investigators are to make colonoscopic video recording of the colon to 
ileum and send the video data to a third-party image reading institution that conducts central reviews. 
Graphic data is to be processed to ensure that individual patients cannot be identified. Colonoscopic video 
recording and graphic data are to be sent following separately outlined procedures. Principal Investigators 
or Sub-investigators are to determine the eligibility of each subject based on the results of central review 
graphic data reading during the screening period. 
 SES-CD scores are calculated by totalling the points for 1. size of ulcers, 2. ulcerated surface, 3. 
affected surface, and 4. presence of stenosis, graded on a 4-point scale (0-3) in each of the five segments: 
Rectum, left colon, transverse colon, right colon, and terminal ileum (Attachment 12). 
 Endoscopic response is defined as a decrease in SES-CD of at least 50% from baseline and endoscopic 
remission is defined as 2 or less points 14 , 15 . 
 
9.5.1.3.3   Evaluation of corticosteroid dose reduction 
 Steroid dose is to be reduced, in principle, using as reference the steroid dose reduction schedule 
outlined in Attachment 9 in subjects who are on concomintant adrenocorticosteroids (including 
concomintant budesonide) and achieve CR100 response. 
 Steroid-free remission is defined as clinical remission (CDAI remission or PRO2-remission) in 
subjects who have become steroid free through steroid reduction. Similarly, steroid-free clinical response 
is defined as clinical response (CR70 response, CR100 response, PRO2-CR5 response and PRO2-CR8 
response) in subjects who have become steroid free through steroid reduction. 
 
9.5.1.4   Assessment items and method for pharmacokinetic, immunogenicity, biomarker 
and pharmacogenomic/pharmacogenetic evaluations 
9.5.1.4.1   Drug concentration assays 
 <Serum E6011 concentration> 
 Blood samples for assaying serum E6011 concentration are to be collected when indicated by the study 
schedule (Table 4). When collecting blood immediately after IMP administration, it should be drawn from 
the opposite side of IMP administration. A validated, specific and selective assay method shall be used to 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 46 of 80 
 
measure serum E6011 concentration at a drug lab. Table 5 and Table 6 show the total amount of blood 
sampled. Samples are to be handled according to the procedures outlined separately. 
 
9.5.1.4.2   Immunogenicity assessment items and method 
 <Serum anti-E6011 antibodies> 
 Blood samples for assaying serum anti-E6011 antibodies are to be collected when indicated by the 
study schedule (Table 4). A validated, specific and selective assay method shall be used to determine the 
presence or absence of serum anti-E6011 antibodies at an immunogenicity lab. In addition, when 
anti-E6011 antibody production is confirmed, the neutralizing activity and isotypes of the anti-E6011 
antibodies shall be evaluated. Table 5 and Table 6 show the total amount of blood sampled. Samples are to 
be handled according to the procedures outlined separately. 
 
9.5.1.4.3   Assessment 
items 
and 
method 
for 
biomarker 
and 
pharmacogenomic/pharmacogenetic evaluations 
 <Total serum FKN concentration> 
 Blood samples for assaying total serum FKN concentration are to be collected when indicated by the 
study schedule (Table 4). Table 5 and Table 6 show the total amount of blood sampled. Samples are to be 
handled according to the procedures outlined separately. Assays are performed by a biomarker lab. 
 
 <Serum CRP concentration> 
 Blood samples for assaying serum CRP concentration are to be collected when indicated by the study 
schedule (Table 4). Table 5 and Table 6 show the total amount of blood sampled. Samples are to be 
handled according to the procedures outlined separately. Assays are performed by the central laboratory. 
 
 <Faecal calprotectin concentration> 
 Samples for assaying faecal calprotectin concentration are to be collected when indicated by the study 
schedule (Table 4). Samples are to be handled according to the procedures outlined separately. Assays are 
performed by the central laboratory. 
 
 <Blood CD16+ monocytes, etc.> 
 Samples for an exploratory measurement of the ratios of blood CD16+ monocytes, etc. are to be 
collected when indicated by the study schedule (Table 4). Flow cytometric subset analysis of peripheral 
blood mononuclear cells, etc. is to be carried out. Note that this assay is only carried out for Japanese 
subjects. Table 5 and Table 6 show the total amount of blood sampled. Samples are to be handled 
according to the procedures outlined separately. Assays are performed by the biomarker measurement site. 
 
 <Blood CD16+ monocyte genetic markers > 
 Samples for an exploratory assay of blood CD16+ monocyte, etc. genetic markers are to be collected 
when indicated by the study schedule (Table 4). DNAs of CD16+ monocytes, etc. extracted from blood 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 47 of 80 
 
samples are to be used to analyse DNA methylation status. Table 5 and Table 6 show the total amount of 
blood sampled. Samples are to be handled according to the procedures outlined separately. Assays are 
performed by the biomarker measurement site. 
  
 <To explore Blood biomarkers> 
 Comprehensive proteome analysis is performed using the residual serum (collected for total serum 
FKN concentration, serum E6011 concentration and serum anti-E6011 antibody tests). This analysis is 
performed at the proteome analysis organization. Additional exploratory biomarker studies (e.g.  
comprehensive metabolome analysis, lipidome analysis and analysis by  single/multiplex experimental 
system, etc.) may be added 
 
. Genetic tests are not to be carried out. 
Note that this evaluation and analysis indicated above in this subsection for subjects who enrolled this 
study in accordance with previous version of study protocol (version 6 or earlier) is to be performed only 
when this subject’s concent obtained. 
 
9.5.1.5   Assessment items and method for safety evaluation 
 Assessment items for safety evaluation include the following, as listed in the study schedule (Table 4). 
Adverse events, laboratory test values, vital signs, weight, physical findings, standard 12-lead ECG 
examinations, neurological symptoms and blood CD4+ cell count. 
 
9.5.1.5.1  Adverse event 
An adverse event (AE) is any untoward medical occurrence in a subject. An AE does not necessarily 
have a causal relationship with an IMP. In the present trial, IMP refers to E6011 and the placebo. 
In this clinical trial, an AE is defined as follows. 
• 
Any undesirable or unintended sign (including an abnormal laboratory value), symptom, or illness 
that emerges after signing informed consent, whether or not it has a causal relationship with the 
IMP. When an illness is diagnosed based on signs and symptoms, the illness, rather than 
individual signs/symptoms, is treated as an AE. 
• 
An illness that emerges or aggravation of a pre-existing illness. 
• 
A laboratory value or worsening of a test (e.g., ECG, X-rays) indicative of some symptom 
(including tests not prescribed by the protocol). 
• 
A laboratory value or worsening of a test (e.g., ECG, X-rays) that results in a change of treatment 
method or discontinuation of the clinical trial (including tests not specified in the protocol). 
• 
Recurrence of an episodic medical condition (e.g., headaches) that was not present at the time of 
signing informed consent. 
• 
An abnormal laboratory value that requires some form of intervention, or discontinuation or 
interruption of treatment with the IMP, whether or not it is identified in the protocol. 
 Note that worsening of the underlying disease (Crohn's disease) is not treated as an AE (minor 
fluctuations in CDAI and SES-CD scores are accounted for in efficacy evaluations but are not regarded as 
CCI

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 48 of 80 
 
AEs), except when it worsens beyond expectations (e.g., requiring hospitalization or surgery). 
 All AEs that emerge after signing of informed consent and up to 70 days after the final dose of the IMP 
are to be compiled and recorded in case report forms, whether or not they have a causal relationship with 
the IMP or study procedures. For screening failure subjects whose reason for failure is the onset of an AE, 
the name and seriousness of the AE are to be documented in their case report forms. 
 All abnormal laboratory values judged to be AEs are to be documented in case report forms. Abnormal 
laboratory values do not need to be separately recorded if they are considered to be part of the clinical 
symptoms that have been reported as AEs. It is the responsibility of Principal Investigators and 
Sub-investigators to check every laboratory value and judge whether it is considered an AE. They are to 
judge medically and scientifically whether an abnormal laboratory value should be regarded as an 
independent AE. 
 Every AE must be followed up until it resolves or 70 days after the final dose of the IMP (whichever 
occurs sooner). Serious AEs are to be followed up until they have resolved or until their symptoms have 
stabilised if they are not likely to resolve. 
 Principal Investigators or Sub-investigators are to use all means necessary to classify each AE by its 
severity and relationship with the IMP. 
 
 Severity evaluation of adverse events 
 AEs are evaluated based on three levels of severity (mild, moderate, severe) and documented in case 
report forms. The three levels are defined as follows.  
 Mild  
 Causes discomfort but not to the extent that it interferes with normal daily activities  
Moderate   Causes discomfort to the extent that it interferes with normal daily activities  
 Severe  
 Incapacitated or unable to carry out normal daily activities  
 
 Evaluating the severity of AEs is different from evaluating the seriousness of AEs (see section 
9.5.1.5.2 ). 
 
 Evaluation of causal relationship with the IMP 
 The following points are to be addressed when evaluating the causal relationship between an AE and 
the IMP. 
• 
The temporal relationship between the timing of AE onset and the start of IMP administration 
• 
The course of the AE and particularly the effect of the IMP if the treatment was discontinued or 
resumed 
• 
Whether or not the AE is known to occur with this IMP or similar drugs 
• 
Any risk factors in the target population that increase the likelihood of the AE 
• 
Any confounding factors related to the onset of the AE but unrelated to the IMP 
 
 Classification of causal relationship with the IMP  

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 49 of 80 
 
 Unrelated   No reasonable causal relationship exists between the IMP and AE  
 Related  
 A reasonable causal relationship possibly exists between the IMP and AE  
 
9.5.1.5.2   Serious adverse events and other important occurrence 
 A serious adverse event (SAE) is any untoward medical occurrence in a subject that at any IMP dose: 
• 
Results in death 
• 
Is life-threatening (where "life-threatening" refers to an event in which the subject was at risk of 
death at the time of the event; it does not refer to an event which hypothetically might have caused 
death if it were more severe, or if the administration of the IMP continued) 
• 
Requires hospitalisation or prolongation of hospitalisation 
• 
Results in persistent or significant disability/dysfunction, or 
• 
Causes a congenital anomaly/birth defect (in the child of the subject who received the IMP). 
 
 Other medically important events, i.e., a significant medical event that is not immediately 
life-threatening or results in death or hospitalization, but may jeopardise the subject and may require 
intervention to prevent one of the above stated outcomes is regarded as serious. In such circumstances, 
whether emergency reporting is warranted is judged based on medical and scientific grounds. 
 Pregnancy and breastfeeding shall also be reported using the same procedures as SAEs. AEs resulting 
from overdose, misuse, abuse, and dosing errors shall also be reported using the same procedures as SAEs 
(see section 9.5.4.2 and section 9.5.4.3 ). Such events are to be treated as SAEs only if they fit the above 
definitions. Note that these AEs, whether or not they fit the definitions of SAEs described above, are all to 
be documented in case report forms. 
 SAEs are to be followed up until they have resolved or until their symptoms have stabilised if they are 
not likely to resolve. 
 
 Hospitalization without an AE, such as those described below, are not treated as SAEs. 
• 
Hospitalization for temporary treatment of conditions other than AEs 
• 
Hospitalization that is specified in the protocol in advance 
• 
Hospitalization that was scheduled before signing of informed consent (for a condition that 
required hospitalization before administration of the IMP and did change after administration) 
• 
Hospitalization for IMP administration or for a procedure to gain access to the IMP administration 
route 
• 
Hospitalization for routine procedures to maintain medical devices that have been in use before 
IMP administration (e.g. battery replacement) 
 
9.5.1.5.3   Laboratory tests 
 Table 3 and Table 4 show laboratory tests (blood, urine) and sample collection timing in this clinical 
trial. 
 Haematology tests are to be processed in clinical trial centres and other tests are processed by the 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 50 of 80 
 
central laboratory. Results of haematology tests are to be included in case report forms. The Sponsor and 
clinical trial centres will receive results of other tests from the testing laboratory. Test results reported to 
clinical trial centres are to be retained as source data. Samples for the tests conducted by the central 
laboratory are to be handled according to the procedures outlined separately. 
 If abnormal laboratory values matches the definitions of AE described in the protocol 
(section9.5.1.5.1 ), they are to be documented in case report forms. 
 If an abnormal laboratory value matches one of the definitions of SAE described in the protocol 
(section 9.5.1.5.2 ) the Principal Investigator is to send a SAE Report to the Sponsor by FAX or other 
means (eCRF can also be used for reporting) (section9.5.4.1  Reporting of SAEs). 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 51 of 80 
 
Table 3 Laboratory Tests 
 Category  
 Items  
 Haematology testing  
White blood cell count, red blood cell count, haemoglobin, 
haematocrit, platelet count, differential white blood cell count 
(neutrophils, lymphocytes, monocytes, acidophils, basophils)  
 Blood biochemistry testing  
 
  
 Liver function tests  
Total bilirubin, ALP, AST, ALT,  GTP  
  
 Renal function tests  
BUN, creatinine  
  
 Other tests  
Glucose, albumin, total cholesterol, triglyceride, amylase, inorganic 
phosphate, LDH, CK, total protein, uric acid, Na, K, Cl, Ca, CRP 
 Urinalysis  
pH, protein, glucose, urobilinogen, ketone bodies, occult blood, 
specific gravity, amylase  
 
9.5.1.5.4   Vital signs and weight measurement 
 During the visits specified in the study schedule (Table 4), vital signs [blood pressure (sytolic, 
diastolic: mmHg), pulse rate (bpm), temperature (°C)], height (cm), and weight (kg) are to be measured 
using prescribed methods and documented in case report forms. Blood pressure and pulse rate should be 
measured in the seated or supine position after resting for at least 5 minutes. Blood pressure should 
generally be measured on the same arm each time and, if possible, by the same person. Temperature should 
be taken under the armpit. 
 If vital sign measurement is scheduled after blood collection on the same day, there should be at least a 
30-minute gap between the blood collection and vital sign measurement. 
 
9.5.1.5.5   Physical findings 
 A physical examination is to be conducted during the visits specified in the study schedule (Table 4). 
Results of the examination are to be documented in the records of clinical trial centres. Any changes from 
screening that fit the definition of AE are to be documented in case report forms. 
 
9.5.1.5.6   ECG 
 Standard 12-lead ECG tests are to be conducted when indicated by the study schedule (Table 4). 
 ECGs are performed after 10 minutes of resting while maintaining the resting supine position. The 
results of normal/abnormal assessment made by principal investigators or sub-investigators are to be 
recorded in case report forms. If blood collection is scheduled before ECG on the same day as ECG, there 
should be at least a 30-minute gap between the blood collection and ECG so as to ensure that the blood 
collection does not affect the ECG. Any abnormal ECGs that fit the definition of AE described in the 
protocol (section9.5.1.5.1 ) are to be documented in case report forms as AEs. 
 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 52 of 80 
 
9.5.1.5.7   Other assessment items for safety evaluations 
 <Pregnancy test> 
 Female subjects of childbearing potential are to undergo urine pregnancy test (qualitative, in clinical 
trial centres) when indicated by the study schedule (Table 4), and the test results are to be recorded in case 
report forms. 
 
 <Neurological symptoms> 
 Subjects are to be assessed for the presence or absence of neurological symptoms using the 
neurological symptoms checklist (Attachment 13) when indicated by the study schedule (Table 4), and the 
results are to be recorded in case report forms. Also, if a neurological symptom is suspected whenever 
subjects are examined outside of specified assessment times, a neurological assessment must be performed 
using the neurological symptoms checklist. Any abnormalities that are found after IMP administration 
must be reported to the Sponsor using the “Neurological Symptoms Report (Attachment 14)” sent by FAX, 
etc. and examined by a neurologist or other specialists. Additionally, brain MRI (T1-weighted, FLAIR and 
diffusion-weighted imaging) is to be performed within two weeks and the MRI images submitted to the 
Sponsor. The Sponsor shall immediately forward the information to a PML evaluator and seek advice on 
whether the subject should continue the IMP administration. The IMP administration is to be put on hold 
until the evaluation is completed by the PML evaluator. Such events are to be documented in case report 
forms as AEs. 
 
 < Blood CD4+ cell count > 
 Blood samples for blood CD4+ cell counting are to be collected when indicated by the study schedule 
(Table 4). Table 5 and Table 6 show the total amount of blood sampled. The assay is performed at a lab 
facility and the Sponsor and clinical trial centres will receive results of tests from the lab. Test results 
reported to clinical trial centres are to be retained as source document. Samples are to be handled 
according to the procedures outlined separately. 
 
 <PML assessment> 
 Starting from 70 days after the last administration of the IMP, the onset of PML is to be assessed every 
six months after the last administration of E6011 for two years. Non-PML AEs are not subject to 
assessment. The onset of PML is to be assessed every six months and the results recorded in case report 
forms. A confirmed onset of PML is to be documented as a SAE in case report forms. In this case, a 
“Serious Adverse Event Report” must be submitted to the sponsor. The following details are to be included 
in the “Serious Adverse Event Report” prepared upon confirmation of PML onset. 
Findings related to the definitive diagnosis of PML [such as clinical features, brain MRI findings, 
genetic testing for detection of JC virus (JCV) DNA cerebrospinal fluid, and relevant laboratory results], 
the course from onset to definitive diagnosis, history of treatment for the underlying disease after the end 
of IMP administration, the status of steroid and immunosuppressant use after the end of IMP 
administration, etc. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential  
  
Page 53 of 80 
 
 
9.5.1.6   Other assessment items 
 <Anti-JC virus antibody test> 
 Anti-JCV antibody testing is to be conducted when indicated by the study schedule (Table 4). If 
discontinuing at Week 24 for a lack of CDAI response, the test is to be conducted during the Week 24 visit 
or 28 days after discontinuation. Samples are to be handled according to the procedures outlined 
separately. 
 
9.5.2   Observation/assessment items and the study schedule 
9.5.2.1   Study schedule 
 Table 4 shows the schedule for this clinical trial. 
 Observations and assessments conducted after the start of IMP administration are scheduled beginning 
from the start date (Day 1) of IMP administration. If observations/assessments need to be rescheduled for 
whatever reason during the remission-induction period, they must be conducted within plus or minus 1 day 
of the scheduled date in Week 1 and thereafter plus or minus 3 days of the scheduled dates up to Week 12. 
During the rescue period, they must be conducted within plus or minus 1 day of the scheduled date in 
Week 13 and thereafter plus or minus 3 days of the scheduled dates up to Week 24. During the extension 
period and post-observation period, they must be conducted within plus or minus 7 days of the scheduled 
dates (“within plus 7 days” of “70 days after the last IMP administration”). 
 Assessments during the follow-up period are to be scheduled using calendar days counting from the 
date of the last IMP administration. From the last IMP administration to 2 years thereafter, they must be 
conducted within plus or minus 1 month of the scheduled dates (example: if the last IMP is administered 
on 1 November 2019, the scheduled date follow-up would be 1 May 2020; the window in this case would 
be between 1 April 2020 and 1 June 2020). 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
 
 Date: 18-Apr-2022 version 11.0 
 Confidential  
     Page 54 of 80 
 Table 4 E6011-ET2 Study Schedule (All Subjects)  
 
 
Screening 
period  
 Remission-induction period (double-blind)  
 
 Visit  
 1  
 2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 -  
 Test/Observation Time  
 Days 
-42 to 
 -1 days  
Week 
0 i  
  
Week 
1 
Week 
2  
Week 
4  
Week 
6  
Week 
8  
Week 
10  
 Week 
12  
 
Disco
ntinua
tion j  
Allowed deviations  
 ―  
 ± 1 
day  
 ± 3 
days  
 ± 3 
days  
 ± 3 
days  
 ± 3 
days  
 ± 3 
days  
 ± 3 
days  
 ―  
 Signing of informed consent a  
 ○  
 
 
 
 
 
 
 
 
 
 Demographic characteristics, 
history of present illness  
 ○  
 
 
 
 
 
 
 
 
 
 Past medical history, 
complications  
 ○  
 
 
 
 
 
 
 
 
 
 Inclusion/exclusion criteria 
check  
 ○  
 ○  
 
 
 
 
 
 
 
 
 Colonoscopy b  
 ○  
 
 
 
 
 
 
 
 ○  
 ○  
 IMP administration c  
 
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○ k  
 
Prior treatment and 
concomitant drugs/therapies 
 
 Physical findings  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 Height/weight d  
 ○  
 ○  
 
 ○  
 ○  
 
 ○  
 
 ○  
 ○  
 Vital signs  
 ○  
 ○  
 ○  
 ○  
 ○  
 
 ○  
 
 ○  
 ○  
 Standard 12-lead ECG  
 ○  
 
 
 
 
 
 
 
 ○  
 ○  
 Chest X-ray test  
 ○  
 
 
 
 
 
 
 
 
 
 Neurological symptoms e  
 ○  
 
 
 
 
 
 
 
 ○  
 ○  
 Anti-JCV antibody test  
 ○  
 
 
 
 
 
 
 
 
 ○  
 Blood CD4+ cell test  
 ○  
 
 
 
 
 
 
 
 ○  
 ○  
 Viral test, tuberculosis test  
 ○  
 
 
 
 
 
 
 
 
 
 Pregnancy test f  
 ○  
 ○  
 
 
 
 
 
 
 ○  
 ○  
 C. difficile toxin test  
 ○  
 
 
 
 
 
 
 
 
 
 CDAI, PRO2  
 
 ○o  
 
 ○  
 ○  
 
 ○  
 
 ○  
 ○  
 Haematology test, blood 
biochemistry test, urinalysis  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 Adverse event  
 
 Serum E6011 concentration g, 
h  
 
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 Serum anti-E6011 antibodies 
h  
 
 ○  
 
 ○  
 ○  
 
 ○  
 
 ○  
 ○  
 Serum total FKN 
concentration h  
 
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 Blood CD16+ monocytes, etc. 
(FCM) h  
 
 ○  
 ○  
 ○  
 ○  
 
 
 
 ○  
 ○  
 Blood CD16+ monocyte, etc. 
genetic markers h  
 
 ○  
 ○  
 ○  
 ○  
 
 
 
 ○  
 ○  
 Faecal calprotectin  
 
 ○  
 
 ○  
 ○  
 
 ○  
 
 ○  
 ○  
a. A written consent of the subject is required prior to undergoing tests and medication washout as part of the requirements to 
participate in this clinical trial. 
b. Endoscopic evaluations are performed by a centralised review. 
c. The IMP is to be administered after completing all assessments scheduled for that day (excluding serum E6011 concentration 
immediately after the end of administration). 
d. Height is measured during the screening period (on Visit 1) only. 
e. If abnormal neurological symptoms are found after IMP administration, the patient must be examined by a neurologist and 
undergo brain MRI (T1-weighted, FLAIR and diffusion-weighted imaging) within two weeks. 
f. 
Pregnancy test is conducted only in female subjects of childbearing potential. 
g. Blood samples are collected before and immediately after (within 10 minutes of) IMP administration between Week 0 and Week 
10. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
 
 Date: 18-Apr-2022 version 11.0 
 Confidential  
     Page 55 of 80 
h. Test results are to be retained by the testing laboratories and not to be shared with Principal Investigators, Sub-investigators and 
trial coordinators until code break. Blood CD16+ monocytes, etc. (FCM) is only conducted in Japanese subjects 
i. 
Randomisation is to be performed at baseline (before the start of IMP administration in Week 0). 
j. 
As many specified tests and evaluations as possible should be conducted for the assessment at discontinuation. 
k. E6011 to be administered after the transition to the rescue period or Extensionperiod. 
l. 
PML onset is to be investigated over the phone, etc. at six months, one year, one and a half years, and two years after the final 
IMP dose. 
m. E6011 not to be administered when discontinuing at Week 24 for a lack of CDAI response. 
n. To be conducted during the Week 24 visit or 28 days after discontinuation only when discontinuing at Week 24 for a lack of 
CDAI response. 
o. 
The hematocrit value used to calculate the CDAI score at Week 0 or screening test (screening test value may also be used if this 
is within 7 days of the date of the CDAI assessment). 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
 
 Date: 18-Apr-2022 version 11.0 
 Confidential  
     Page 56 of 80 
p.  Table 4 E6011-ET2 Study Schedule (Responders)  
 
 Extension period (open-label)  
 
Post-observ
ation period  
 
Follow-
up 
 period  
 Visit  
 10   11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 -  
 20  
 21  
 -  
 Test/Observation Time  
 
 
Week 
16 
 
  
Week 
 20  
  
Week 
24  
  
Week 
 28  
  
Week 
 32  
  
Week 
 36  
  
Week 
 40  
  
Week 
 44  
  
Week 
 48  
  
Week 
52  
  
Disconti
nuation j 
 28 
days 
after 
compl
etion/
disco
ntinua
tion 
  
 70 
days 
after 
last 
dose 
administr
ation  
 
 
 2 years 
after last 
dose 
administrat
ion l 
Allowed deviations 
 ± 7 
days  
 ± 7 
days  
 ± 7 
days  
 ± 7 
days  
 ± 7 
days  
 ± 7 
days  
 ± 7 
days  
 ± 7 
days  
 ± 7 
days  
 ± 7 
days  
 -  
 ± 7 
days  
 +7 
days  
 ± 1 
month  
 Signing of informed consent 
a  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Demographic characteristics, 
history of present illness  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Past medical history, 
complications  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Inclusion/exclusion criteria 
check  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Colonoscopy b  
 
 
  
 
 
 
 
 
 
 ○  
 ○  
 
 
 
 IMP administration c  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 
 
 
 
 
 Prior treatment and 
concomitant drugs/therapies  
 
 
 
 
 Physical findings  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
○ 
○ 
○ 
○ 
○ 
○ 
 
 
Height/weight d 
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 
 
 
 Vital signs  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 
 
 Standard 12-lead ECG  
 
 
 ○  
 
 
 ○  
 
 
 
 ○  
 ○  
 
 
 
 Chest X-ray test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Neurological symptoms e  
 
 
 ○  
 
 
 ○  
 
 
 
 ○  
 ○  
 
 
 
 Anti-JCV antibody test  
 
 
 
 
 
 
 
 
 
 ○  
 ○  
 
 
 
 Blood CD4+ cell test  
 
 
 
 
 
 ○  
 
 
 
 ○  
 ○  
 
 
 
 Viral test, tuberculosis test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Pregnancy test f  
 
 
 
 
 
 
 
 
 
 ○  
 ○  
 
 
 
 C. difficile toxin test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CDAI, PRO2  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 
 
 
 Haematology test, blood 
biochemistry test, urinalysis  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 
 
 Adverse event  
 
 (PML)  
 Serum E6011 concentration 
g, h  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 
 
 
 Serum anti-E6011 antibodies 
h  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 
 
 
 Serum total FKN 
concentration h  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood CD16+ monocytes, etc. 
(FCM)h 
 
 
 ○  
 
 
 
 
 
 
 ○  
 ○  
 
 
 
Blood CD16+ monocyte, etc. 
genetic markersh 
 
 
 ○  
 
 
 
 
 
 
 ○  
 ○  
 
 
 
 Faecal calprotectin  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 
 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
 
 Date: 18-Apr-2022 version 11.0 
 Confidential  
     Page 57 of 80 
Table 4 E6011-ET2 Study Schedule (Non-responders) 1/2  
 
 Rescue period (open-label)  
 
 Visit  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 -  
 Test/Observation Time  
  
Week 
13  
 Week 
14  
 Week 
16  
 Week 
18  
 Week 
20  
 Week 
22  
 Week 
24  
 
Discont
inuatio
n j  
 Allowed deviations 
 ± 1 day  
 ± 3 
days  
 ± 3 
days  
 ± 3 
days  
 ± 3 
days  
 ± 3 
days  
 ± 3 
days  
 --  
 Signing of informed consent 
a  
 
 
 
 
 
 
 
 
 Demographic characteristics, 
history of present illness  
 
 
 
 
 
 
 
 
 Past medical history, 
complications  
 
 
 
 
 
 
 
 
 Inclusion/exclusion criteria 
check  
 
 
 
 
 
 
 
 
 Colonoscopy b  
 
 
 
 
 
 
 
 
 IMP administration c  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 (○)m 
 
 Prior treatment and 
concomitant drugs/therapies  
 
 Physical findings  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 Height/weight d  
 
 ○  
 ○  
 
 ○  
 
 ○  
 ○  
 Vital signs  
 ○  
 ○  
 ○  
 
 ○  
 
 ○  
 ○  
 Standard 12-lead ECG  
 
 
 
 
 
 
 ○  
 ○  
 Chest X-ray test  
 
 
 
 
 
 
 
 
 Neurological symptoms e  
 
 
 
 
 
 
 ○  
 ○  
 Anti-JCV antibody test  
 
 
 
 
 
 
 (○) n  
 ○  
 Blood CD4+ cell test  
 
 
 
 
 
 
 ○  
 ○  
 Viral test, tuberculosis test  
 
 
 
 
 
 
 
 
 Pregnancy test f  
 
 
 
 
 
 
 ○  
 ○  
 C. difficile toxin test  
 
 
 
 
 
 
 
 
 CDAI, PRO2  
 
 ○  
 ○  
 
 ○  
 
 ○  
 ○  
 Haematology test, blood 
biochemistry test, urinalysis  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 Adverse event  
 
 Serum E6011 concentration 
g, h  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 ○  
 Serum anti-E6011 antibodies 
h  
 
 ○  
 ○  
 
 ○  
 
 ○  
 ○  
 Serum total FKN 
concentration h  
 
 
 
 
 
 
 
 
Blood CD16+ monocytes, etc. 
(FCM) h 
 
 
 
 
 
 
 
 
 Blood CD16+ monocyte, etc. 
genetic markers h  
 
 
 
 
 
 
 
 
 Faecal calprotectin  
 
 ○  
 ○  
 
 ○  
 
 ○  
 ○  

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
 
 Date: 18-Apr-2022 version 11.0 
 Confidential  
     Page 58 of 80 
 
 Table 4 E6011-ET2 Study Schedule (Non-responders) 2/2  
 
 Extension period (open-label)  
 
Post-observatio
n period  
 
Follow-
up 
 period  
 Visit  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
 -  
 27  
 28  
 
 Test/Observation Time  
  
 Week
28  
  
Week
32  
  
Week 
36  
  
Week 
40  
  
Week
44  
  
 Week
48  
  
Week 
52  
  
Week 
56  
  
Week 
60  
 
Week 
64  
 
Discontin
ation j 
 28 
days 
after 
completi
on/disco
ntinuati
on 
 
  
 70 
days 
after last 
dose 
administ
ration 
 
  
 
 
 2 years 
after last 
dose l 
administrat
ion  
 Allowed deviations 
 ± 7 
days 
 ± 7 
days 
 ± 7 
days  
 ± 7 
days  
 ± 7 
days 
 ± 7 
days 
 ± 7 
days 
± 7  
days  
 ± 7 
days  
 ± 7 
days 
 -  
 ± 7 
days  
 +7 
days  
 ± 1 
month  
 Signing of informed consent 
a  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Demographic characteristics, 
history of present illness  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Past medical history, 
complications  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Inclusion/exclusion criteria 
check  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Colonoscopy b  
 
 
  
 
 
 
 
 
 
 ○  
 ○  
 
 
 
 IMP administration c  
 ○   ○   ○   ○   ○   ○   ○   ○   ○  
 
 
 
 
 
 Prior treatment and 
concomitant drugs/therapies  
 
 
 
 
 Physical findings  
 ○   ○   ○   ○   ○   ○   ○   ○   ○   ○  
 ○  
 ○  
 
 
Height/weight d 
 ○   ○   ○   ○   ○   ○   ○   ○   ○   ○  
 ○  
 
 
 
 Vital signs  
 ○   ○   ○   ○   ○   ○   ○   ○   ○   ○  
 ○  
 ○  
 
 
 Standard 12-lead ECG  
 
 
 ○  
 
 
 ○  
 
 
 
 ○  
 ○  
 
 
 
 Chest X-ray test  
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 Neurological symptoms e  
 
 
 ○  
 
 
 ○  
 
 
 
 ○  
 ○  
 
 
 
 Anti-JCV antibody test  
 
 
 
 
 
 
 
 
 
 ○  
 ○  
 (○) n  
 
 
 Blood CD4+ cell test  
 
 
 
 
 
 ○  
 
 
 
 ○  
 ○  
 
 
 
 Viral test, tuberculosis test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Pregnancy test f  
 
 
 
 
 
 
 
 
 
 ○  
 ○  
 
 
 
 C. difficile toxin test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CDAI, PRO2  
 ○   ○   ○   ○   ○   ○   ○   ○   ○   ○  
 ○  
 
 
 
 Haematology test, blood 
biochemistry test, urinalysis  
 ○   ○   ○   ○   ○   ○   ○   ○   ○   ○  
 ○  
 ○  
 
 
 Adverse event  
 
 (PML)  
 Serum E6011 concentration 
g, h  
 ○   ○   ○   ○   ○   ○   ○   ○   ○   ○  
 ○  
 
 
 
 Serum anti-E6011 antibodies 
h  
 ○   ○   ○   ○   ○   ○   ○   ○   ○   ○  
 ○  
 
 
 
 Serum total FKN 
concentration h  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood CD16+ monocytes, etc. 
(FCM) h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Blood CD16+ monocyte, etc. 
genetic markers h  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Faecal calprotectin  
 ○   ○   ○   ○   ○   ○   ○   ○   ○   ○  
 ○  
 
 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 59 of 80  
 
9.5.2.2   Total amount of blood sampled 
 Table 5 and Table 6 show the number of blood sampling and the total amount of blood sampled 
throughout the trial period. More blood may be collected if a test value is outside the normal range or 
when a Principal Investigator or Sub-investigator decides it is necessary to confirm the safety of a subject. 
 
Table 5 The total amount of blood sampled (Responders)  
 Item  
 Amount of 
blood 
sampled per 
collection  
 Screening 
period  
 
Remission-induction 
period  
 Extension 
period  
 After 
administration 
 Observation 
period  
 Days -41 to 
-1  
 Weeks 0-12  
 Weeks 
13-52  
 Weeks 53-56  
 Viral test, tuberculosis test  
 18 mL  
 1 sample  
 
 
 
 Haematology testing *  
 (2 mL)  
 1 sample  
 8 samples  
 10 samples  
 1 sample  
 Blood biochemistry testing  
 5 mL  
 1 sample  
 8 samples  
 10 samples  
 1 sample  
 Blood CD4+ cell count  
 5 mL  
 1 sample  
 1 sample  
 2 samples  
 
 Anti-JCV antibodies  
 3.5 mL  
 1 sample  
 (Note 1)  
 1 sample  
 
Serum E6011 concentration 
(Before E6011 
administration) 
 2 mL  
 
 8 samples  
 10 samples  
 
Serum anti-E6011 antibodies 
 5 mL 
 
 5 samples 
 10 samples  
 
Serum total FKN 
concentration 
 2 mL 
 
 8 samples  
 
 
Serum E6011 concentration 
(immediately after the end 
of E6011 administration 
(within 10 minutes)) 
 2 mL  
 
 7 samples  
 
 
Blood CD16+ monocytes, 
etc. (FCM) (Note 2)  
 5 mL  
 
 5 samples  
 2 samples  
 
Blood CD16+ monocyte, etc. 
genetic marker 
 5 mL  
 
 5 samples  
 2 samples  
 
 Amount of blood sampled  
 33.5 mL  
 185.5 mL  
  173.5 mL  
 7 mL  
 The total amount of blood sampled up to 
Week 12  
 219 mL  
 
 The total amount of blood sampled up to 
Week 52  
392.5 mL  
 
 The total amount of blood sampled up to 
Week 56  
  399.5 mL  
 *Haematology testing is done in clinical trial centre. The total amount of blood sampled is calculated by using 2 mL 
as the amount of blood required per collection. 
 Note 1: If a subject is discontinuing during the remission-induction period, one sample (3.5 mL) of blood is collected 
at discontinuation testing. 
 Note 2: Blood CD16+ monocytes, etc. (FCM) is only conducted in Japanese subjects. 
 
 
 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 60 of 80  
 
 
Table 6 The total amount of blood sampled (Non-responders)  
 Item  
 Amount 
of blood 
sampled 
per 
collection  
 Screening 
period  
 
Remission-induction 
period  
 Rescue 
period  
 Extension 
period  
 After 
administration 
 Observation 
period  
 Days -41 
to -1  
 Weeks 0-12  
Weeks 
13-24 
 Weeks 25- 
64  
 Weeks 65-68  
Viral test, tuberculosis 
test 
 18 mL  
 1 sample  
 
 
 
 
Haematology testing * 
 (2 mL)  
 1 sample  
 8 samples  
 7 samples  
 10 
samples  
 1 sample  
Blood biochemistry 
testing 
 5 mL  
 1 sample  
 8 samples  
 7 samples  
 10 
samples  
 1 sample  
Blood CD4+ cell count 
 5 mL  
 1 sample  
 1 sample  
 1 sample  
 2 samples  
 
Anti-JCV antibodies 
 3.5 mL  
 1 sample  
 (Note 1)  
 (Note 2)  
 1 sample  
 (Note 2)  
Serum E6011 
concentration 
(Before E6011 
administration) 
 2 mL  
 
 8 samples  
 7 samples  
 10 
samples  
 
Serum anti-E6011 
antibodies 
 5 mL 
 
 5 samples  
 4 samples  
 10 
samples  
 
Serum total FKN 
concentration 
2 mL 
 
 8 samples  
 
 
 
Serum E6011 
concentration 
(immediately after the 
end of E6011 
administration) 
(within 10 minutes)) 
 2 mL  
 
 7 samples  
 
 
 
Blood CD16+ monocytes, 
etc. (FCM) (Note 3) 
 5 mL  
 
 5 samples  
 
 
 
Blood CD16+ monocyte, 
etc. genetic marker 
 5 mL  
 
 5 samples  
 
 
 
 Amount of blood sampled  
 33.5 mL  
 185.5 mL  
 91.5 mL  
 153.5 mL  
 10.5 mL  
 The total amount of blood sampled up 
to Week 12  
 219 mL  
 
 
 
 The total amount of blood sampled up 
to Week 24  
 310.5 mL  
 
 
 The total amount of blood sampled up 
to Week 64  
 464 mL  
 
 The total amount of blood sampled up 
to Week 68  
 474.5 mL  
 *Haematology testing is done in clinical trial centre. The total amount of blood sampled is calculated by using 2 mL as 
the amount of blood required per collection. 
 Note 1: If a subject is discontinuing during the remission-induction period, one sample (3.5 mL) of blood is collected at 
discontinuation testing. 
 Note 2: One blood sample (3.5 mL) to be collected when discontinuing at Week 24 or 28 days after discontinuation for a 
lack of CDAI response. 
 Note 3: Blood CD16+ monocytes, etc. (FCM) is only conducted in Japanese subjects. 
 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 61 of 80  
 
9.5.3   Suitability of assessment items 
<Efficacy> 
The proportion of subjects with CDAI reductions of at least 70 points from baseline (CR70 response 
rate), CR 100 response rate, and the proportion of subjects with CDAI below 150 points (CDAI remission 
rate) by using the CDAI score were chosen as the efficacy endpoints of this clinical trial. As the sample 
size was determined for this clinical trial based on the CR100 response rate used as an efficacy endpoint in 
the 101 trial, it was deemed appropriate to use the CDAI score that includes CR100 response rate. 
Meanwhile the EMA guidelines have pointed out problems with the CDAI score, suggesting that clinical 
symptoms and mucosal inflammation be independently evaluated. Accordingly, as secondary endpoints, 
clinical symptoms will be evaluated with PRO2 and mucosal inflammation with the SES-CD using 
colonoscopy. Likewise, based on the EMA guidelines, steroid-free remission rate and response rate will 
also be evaluated in subjects on concomitant corticosteroids. 
 
<Safety> 
 For the evaluation of safety in this clinical trial, adverse events, laboratory test values, vital signs, 
weight, physical findings, 12-lead ECG, neurological symptoms and blood CD4+ cell count will be used as 
indices for evaluating subjects’ safety. Additionally, the following tests will be conducted 
  
<The risk of PML> 
 The risk of PML has been reported as a rare side effect of natalizumab (humanised monoclonal 
antibody against α4-integrin), which is used in the treatment of Crohn's disease and multiple sclerosis 16 . 
The mechanism of onset remains unclear but has been linked to α4-integrin. There have been no 
findings that suggest PML in the previous clinical trials. However, the possibility of E6011 indirectly 
affecting α4-integrin cannot be ruled out completely because, although its mechanism of action is 
neutralizing FKN, the actions of integrins have been shown to increase due to the interaction of FKN 
and CX3CR1 17 . For this reason, a PML risk-related exclusion criterion was established such that 
subjects with a CD4+ cell count under 200/μL, WBC count under 3,000/μL, or with abnormal 
neurological symptoms are to be excluded. In addition, subjects are to be regularly assessed for 
neurological symptoms throughout the clinical trial and a system is to be put in place such that PML 
evaluators are available to provide their opinions on PML diagnosis and treatment (if abnormal 
neurological symptoms are found after IMP administration, the subject must be examined by a 
neurologist and undergo brain MRI within two weeks, and the IMP administration is to be put on hold 
until the evaluation is completed by a PML evaluator). Furthermore, although the mechanism of onset 
of PML is not completely understood, neurological disturbances are believed to be caused by 
reactivation of the latent JCV which becomes activated by reduced cellular immunity 18 , Anti-JCV 
antibody testing is to be conducted and information is to be collected during screening period and at 
completion (discontinuation) of the IMP administration, and PML onset is to be investigated over the phone, 
etc. every 6 months in the two-year follow-up period after the last IMP administration.. 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 62 of 80  
 
9.5.4   Reporting of SAEs, pregnancy and other important AEs 
9.5.4.1   Reporting of SAEs 
 Investigators are to report every serious adverse event, whether or not it has a causal relationship with 
the IMP, to the sponsor by sending a SAE Report by FAX, etc. (eCRF can also be used for reporting) as 
soon as possible (no later than 24 hours) upon receiving the information. 
 All SAEs that emerge up to 70 days after the last dose administration of the IMP are to be compiled, 
whether or not they have a causal relationship with the IMP or study procedures. All SAEs are to be 
followed up until they have resolved or until their symptoms have stabilised if they are not likely to 
resolve. Any SAEs for which causal relationship with the IMP (or procedures specified in the protocol) 
cannot be ruled out in the opinion of a principal investigators or sub-investigator are to be reported to the 
sponsor regardless of the amount of time that has passed after the end of clinical trial. 
 After the end of IMP administration, during the two-year follow-up period, only the onset of PML is to 
be assessed. 
 Safety-related Emergency Contact Details are provided in Attachment 2 1.4.1. 
 It is important that SAE Reports are as complete as possible at the time of initial reporting, including 
the principal investigator’s or sub-investigator’s evaluation of causal relationship with the IMP. 
 Whenever additional information on SAEs is received, the investigator is to contact the sponsor’s 
representative within one day after the receipt. If the additional information changes the evaluation of 
causal relationship with the IMP, the change is to be described in the SAE Report (eCRF can also be used 
for reporting). 
 If the sponsor requests additional information regarding the details of a SAE Report, the clinical trial 
centre shall provide without delay detailed supplementary information, including copies of medical record, 
autopsy report, and other documents. 
 
9.5.4.2   Reporting of pregnancy and breastfeeding 
 Any time when a pregnancy is estimated to have occurred in a female subject (or the female partner of 
a subject) prior to the last visit or within 70 days of the last dose administration of the IMP, or when a 
subject breastfeeds while receiving the IMP or within 70 days of the last dose administration of the IMP, it 
must be reported. 
 Poor pregnancy outcomes that are suspected to be causally related to the IMP must be reported 
regardless of the amount of time that has passed after IMP administration. 
 Miscarriages, abortions, congenital abnormalities, and still births are considered serious adverse events 
and to be reported with the same method and in the same time frame as SAEs (see section9.5.4.1 
Reporting of SAEs). 
 Whenever information on a pregnancy or breastfeeding is received, the investigator is to report it to the 
sponsor by FAX or email without delay (within one day at the latest). The contact details for reporting a 
pregnancy or breastfeeding are the same as the Safety-related Emergency Contact Details described in 
section 9.5.4.1 . The Pregnancy-related Report (Attachment 15) is to be used. In addition, investigators are 
to confirm the pregnancy outcomes and report the information to the sponsor using the form for reporting 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 63 of 80  
 
pregnancy-related information (Attachment 16: Pregnancy-related Report) without delay (within one day 
at the latest). 
 Subjects who have become pregnant are to be withdrawn from the clinical trial. 
 
9.5.4.3   Reporting of other notable occurrences 
9.5.4.3.1   Reporting of AEs resulting from overdose, misuse, abuse, and dosing 
errors 
 AEs resulting from overdose, misuse, abuse, and dosing errors are the AEs that occur when the IMP is 
administered (or ingested by the subject) differently than as specified by the protocol. The definitions of 
overdose, misuse, abuse, and dosing error are as follows. 
 
 Overdose  
 Accidental or intentional administration (or ingestion) of the IMP in quantities 
greater than that is specified in the protocol  
 Misuse  
 Administration (or ingestion) of the IMP intentionally or inappropriately not 
according to the method of administration specified in the protocol  
 Abuse  
 Intentional administration (or ingestion) of the IMP in excess quantities temporarily 
or continuously with adverse physical or mental effects.  
 Dosing 
error  
 Any accidental event that triggers or becomes a cause of inappropriate use of the 
IMP or adverse effects on a subject, despite the proper management of the IMP by the 
clinical trial centre or subject.  
 
 All AEs resulting from overdose, misuse, abuse, or a dosing error are to be documented in case report 
forms and reported according to the procedure specified in section9.5.4.1  Reporting of SAEs (including 
those that do not fit the definition of SAE). All cases of abuse are to be treated as AEs. While AEs resulting 
from overdose, misuse, abuse, and dosing errors that do not fit the definition of SAE are also to be 
reported according to the emergency reporting procedure using the SAE Report form, they are documented 
as non-serious AE in SAE Reports and case report forms (eCRF can also be used for reporting). 
 
9.5.4.4   Emergency reporting 
 In accordance with regulations and emergency reporting procedure of the respective region (and within 
the region-specific time frame) the sponsor must report reportable AEs to principle investigators, directors 
of clinical trial centres, and regulatory authorities. For this reason, principal investigators or 
sub-investigators are to report all the information on the SAE Report form according to the procedure 
outlined in “Reporting of SAE” (section9.5.4.1 ). 
 
9.5.4.5   Unblinding 
 In case of a medical emergency, investigators will be able to break the code of the applicable subject if 
it is necessary to know the subject’s IMP allocation for ensuring the subject’s treatment and safety. In such 
cases, the AEs that led to emergency code break are to be treated as SAEs and the procedure outlined in 
“Reporting of SAEs” (section9.5.4.1 ) is to be followed. All code breaks must be clearly documented with 
reason and justification. In addition, unblinding must immediately be reported to the sponsor. 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 64 of 80  
 
 The procedure for emergency code break is as follows. 
 [[Emergency code break procedure]] 
(1) The requester of code break (investigators or the sponsor) enters necessary information (names of 
clinical trial centre/department, subject’s ID code, date of birth, drug number, and reason for code 
brake) into the IWRS in order to perform an emergency code break for the applicable subject and 
places their signature. 
(2)Upon completion of code break, the e-mail will be distributed to the sponsor. 
 
9.5.4.6   Reporting of AEs to regulatory authorities 
 Adverse events are reported to regulatory authorities in accordance with local laws and laws of each 
region and with the guidance set forth by the sponsor or its third-party representative. Forms used for 
reporting are as per local regulations and regulations of each region. 
 All clinical trials carried out in European countries shall adhere to European Good Clinical Practice 
Directive 2005/28/EC and European Clinical Trial Directive 2001/20/EC. All suspected unexpected 
serious adverse reactions (SUSARs) are to be reported to competent authorities of involved European 
countries in accordance with the regulations. 
 
9.5.5   Subject completion and withdrawal 
 The subjects themselves may request to discontinue participating in the clinical trial at any time 
without providing explanation. All subjects who discontinue the clinical trial after the start of the IMP 
administration are to undergo assessments at discontinuation outlined in the study schedule (Table 4) 
 The principal investigator or sub-investigator shall promptly inform the subject of the discontinuation, 
provide appropriate medical care and take other necessary measures. If a subject fails to make hospital 
visits, follow-up assessments of the reason, medication status, AEs, the progression of signs and symptoms, 
among others, are to be made as much as possible through letters, phone calls, etc. 
 The main reason (one) among the list of reasons (onset of AE, lost to follow-up, personal reason, 
insufficient therapeutic effect, worsening of underlying disease, consent withdrawal, pregnancy, trial 
discontinuation by the sponsor, other reasons) is to be recorded in the case report forms of dropout 
subjects. 
 
9.5.6   IMP abuse (or IMP diversion to non-subjects) 
Not applicable. 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 65 of 80  
 
9.5.7   Checks for medical care at another department/another hospital 
Principal investigators, sub-investigators, and clinical research coordinators are to instruct subjects to 
contact them in advance when planning to receive medical care at another department or another hospital 
for the first time. In addition, principal investigators, sub-investigators, and clinical research coordinators 
are to check with subjects at each visit whether they have been seen at another department or another 
hospital since their last visit and if they plan to do so. If a subject has a plan to be seen at another 
department or another hospital, the principal investigator or sub-investigator is to inform the attending 
physician of the subject’s trial participation with the subject’s consent. 
 
9.6   Quality assurance of the data 
This clinical trial shall be conducted in compliance with the protocol, SOPs, operational manual, 
applicable guidelines and regulations. Auditors independent of the department conducting the clinical trial 
are to regularly audit clinical trial centres. 
 
9.6.1   Data collection 
 Required data as specified by the protocol are to be collected using case report forms and the 
information is to be entered into data management systems that conform to regulations. As specified in 
ICH GOP, case report forms are printed records, readable records or electronic records, designed to collect 
all the protocol-specified information on each subject and report it to the sponsor. 
 Collecting data for case report form shall follow the manual for creating case report forms. Principal 
investigators are responsible for all the data collected in case report forms and reported. By placing their 
signatures, principal investigators must guarantee the accuracy, reliability and completeness of the data. 
 The sponsor has the ownership of the original case report forms containing the complete data. They 
must not be disclosed through any means, without a written permission of the sponsor, to a third party, 
except those clinical trial personnel designated by the sponsor and representatives from the regulatory 
authorities of each region. 
 
9.6.2   Management of clinical trial data 
 The sponsor will collect data using a standard computer system and software. The system and software 
have been validated and in compliant with the regulations. Additionally, all data from case report forms 
and other external data (e.g., laboratory values) will be entered into the clinical trial database using the 
above-mentioned system. 
 
9.7   Statistical method 
 For analysis, SAS ® or other validated statistical software will be used as needed. In this clinical trial, 
analysis of the remission-induction period is to begin once the remission-induction period database has 
been locked and unblinded. Analysis of the entire administration period is to be performed once the 
database for the entire dosing period (remission-induction period, rescue period, extension period, and 
follow-up post-observation period) has been locked. Analysis of the follow-up period is to begin after the 
follow-up period database has been locked. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 66 of 80  
 
 Details are described in the statistical analysis plan. The analysis plan will be fixed before locking 
databases for each of the remission-induction period, the entire administration period and follow-up 
period. 
 
9.7.1   Statistical and analysis plan 
 This section outlines the analysis of clinical trial data. From here to section 9.7.1.9 mainly describes 
the analysis of the remission-induction period, while section 9.7.1.10 and section 9.7.1.11 describe the 
analysis of the entire administration period and follow-up period. 
 
9.7.1.1   Endpoints 
9.7.1.1.1   Primary endpoint 
 <Primary endpoint> 
 CR100 response rate at Week 12 
 
9.7.1.1.2   Secondary endpoints 
 <Secondary endpoints> 
• 
CR70 response rate, CR100 response rate (excluding Week 12) and CDAI remission rate 
(proportion of subjects with below 150 points) at each evaluation time 
• 
Proportion of subjects with at least 5-point reduction in PRO2 from baseline (PRO2-CR5 response 
rate), proportion of subjects with at least 8-point reduction from baseline (PRO2-CR8 response 
rate), and proportion of subjects with below 8 points (PRO2-resmission rate) at each evaluation 
time 
• 
Proportion of subjects with at least 50% improvement in SES-CD score from prior to IMP 
administration (endoscopic response rate) and proportion of subjects with 2 or less in SES-CD 
score (endoscopic remission rate) at Week 12  
• 
Change and percent change in CDAI score from baseline at each evaluation time 
• 
Change and percent change in PRO2 from baseline at each evaluation time 
• 
Change and percent change in SES-CD score from baseline at Week 12 
• 
In subjects who were concomintantly taking adrenocorticosteroid, proportion of subjects who 
achieved steroid-free maintenance (steroid-free remission rate, steroid-free improvement rate) 
through steroid dose reduction and clinical remission (CDAI remission or PRO2 remission) or 
clinical improvement (CR70 response, CR100 response, PRO2-CR5 response or PRO2-CR8 
response)  
• 
In subjects who were concomintantly taking adrenocorticosteroid, dosage, change and percent 
change of adrenocorticosteroid from baseline 
 
9.7.1.2   Definition of the analysis population 
 FAS (full analysis set) is a set of subjects to whom the IMP has been administered after randomisation, 
and who had 1 or more evaluable, post-IMP administration primary efficacy endpoint data points. 
 PPS (per protocol set) is a set of subjects who satisfactorily complied with the Protocol. Detailed 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 67 of 80  
 
criteria deemed to match present analysis sets are to be decided upon before the database is locked and 
unblinded, and they are to be specified in the analysis plan. 
 Safety analysis set is a set of subjects to whom the IMP has been administered, and who had 1 or more 
evaluable, post-IMP administration safety data. 
 Pharmacokinetic analysis set is a set of subjects to whom the IMP has been administered, and who had 
1 or more evaluable, post-IMP administration serum E6011 concentration data points. 
 Pharmacodynamic analysis set is a set of subjects to whom the IMP has been administered, and who 
had 1 or more evaluable, post-IMP administration biomarker data points. 
 
9.7.1.3   Breakdown of subjects 
 Consented subjects and screening failure subjects with reason for screening failure are to be 
summarised. Additionally, randomised subjects, untreated subjects (after randomization), treated subjects, 
completed subjects, discontinued subjects with reason for discontinuation are to be summarised by 
allocated treatment group. 
 
9.7.1.4   Characteristics of demographic and pre-treatment values 
 Characteristics of demographic and other pre-treatment values are to be presented for the FAS and 
safety analysis set. Continuous variables include age, weight, height, and biomarkers. Categorical variables 
include sex and race. 
 
9.7.1.5   Prior treatment and concomitant treatment 
 Drugs recoded in case report forms should be listed using the 11-character drug codes of the World 
Health Organization Drug Dictionary (WHO DD). The number of subjects (percentage) receiving prior 
treatment drugs and concomitant drugs is to be calculated for each treatment group using the FAS. 
Furthermore, it is to be calculated for each Anatomical Therapeutic Chemical (ATC) classification (if 
classified into applicable ATC classes, such as the anatomical class, therapeutic class, pharmacologic class, 
and chemical class) and WHO DD preferred term. A prior treatment drug is defined as a drug discontinued 
prior to the start of IMP administration. A concomitant drug is defined as “when a drug that was started 
prior to IMP administration continues to be used at the start of IMP administration” or “a drug that was 
started during the IMP administration period and used before the end of the extension period (or 
discontinuation)”. Prior treatments and concomitant treatments are to be categorised into “drugs” or 
“non-drug therapies” and presented in a table. 
 
9.7.1.6   Efficacy analysis 
 Efficacy analysis will be performed using the FAS as the primary analysis set, while the PPS will be 
used as a supplementary analysis set. 
 
9.7.1.6.1   Analysis of primary efficacy endpoint 
 For Week 12 CR100 response rate, the Bayesian posterior distribution of the difference in the CR100 
rate at Week 12 between the E6011 group and the placebo group is to be calculated. If there was a 50% or 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 68 of 80  
 
more probability of the difference between both groups being 25% or more, the efficacy of E6011 is 
confirmed. Noninformative prior distribution is to be used for both the E6011 group and the placebo 
group. 
 Subjects with missing primary endpoint data due to premature discontinuation before 12 weeks after 
administration or other reasons are treated as non-responders - non-responder imputation (NRI). 
 
9.7.1.6.2   Analysis of secondary efficacy endpoints 
  CDAI response rate [CR70, CR100 (excluding Week 12)] and remission rate are to be calculated by 
treatment group and evaluation time. Summary statistics for CDAI value, change and percent change 
from baseline are also to be calculated by treatment group and evaluation time. 
  PRO2 response rate (PRO2-CR5, PRO2-CR8) and remission rate are to be calculated by treatment 
group and evaluation time. Summary statistics for PRO2 value, change and percent change from 
baseline are also to be calculated by treatment group and evaluation time. 
  SES-CD endoscopic response rate and endoscopic remission rate are to be calculated by treatment 
group and evaluation time. Summary statistics for SES-CD value, change and percent change from 
baseline are also to be calculated by treatment group and evaluation time. 
 Steroid-free remission rate and steroid-free response rate in subjects concomitantly using 
adrenocorticosteroids is to be tabulated by treatment group and evaluation time. Summary statistics for 
steroid dosage, change and percent change from baseline are also to be calculated for each treatment 
group and evaluation time. 
 
 Subjects with missing secondary endpoint data due to premature discontinuation before 12 weeks after 
administration or other reasons are treated as non-responders (NRI) in the analysis of secondary endpoints. 
 
9.7.1.7   Analysis 
of 
pharmacokinetics, 
pharmacodynamics, 
pharmacogenomics/pharmacogenetics and other biomarker evaluations 
9.7.1.7.1   Pharmacokinetic analysis 
 Serum E6011 concentration is to be summarised using the pharmacokinetic analysis set. Summary 
statistics for serum E6011 concentration are to be calculated for each specified time. Serum E6011 
concentration-time profile is also to be created. 
 
9.7.1.7.2   Analysis of pharmacodynamics, pharmacogenomics/pharmacogenetics 
and other biomarkers 
 Exploratory biomarker and pharmacogenomic analyses are to be performed using the 
pharmacodynamic analysis set. Summary statistics for serum total FKN concentration, measured faecal 
calprotectin and serum CRP values, change and percent change from baseline are to be calculated by 
treatment group and evaluation time. 
 
 Details and results of the analysis of blood CD16+ monocytes, etc., genetic marker for CD16+ 
monocytes, etc. and blood biomarkers (comprehensive proteome analysis) using the residual serum 
CCI

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 69 of 80  
 
collected for this study will be provided in a separate report and will not be included in the Clinical Study 
Report. 
 
9.7.1.8   Safety analysis 
 Safety is to be analysed using the safety analysis set. Summary statistics related to safety data (sample 
size, mean, standard deviation, median, minimum and maximum for continuous variables; sample size and 
ratio for categorical variables) are to be calculated by treatment group based on the actual treatment 
received. Safety endpoints include adverse events, laboratory values, vital signs, weight, physical 
examination, standard 12-lead ECG, neurological symptoms and blood CD4+ cell count. In safety analysis, 
Day 1 is the start date of IMP administration. 
 
9.7.1.8.1   Exposure status 
 Summary statistics for the numbers of subjects who received the IMP, the exposure period, and dose 
are to be presented by treatment group. 
 
9.7.1.8.2   Adverse event 
 Adverse events in case report forms are to be reworded using the ICH medical terminology (MedDRA). 
Using MedDRA (Version 21.0 or later), terms used in case report forms are reworded the closest Lowest 
Level Term (LLT). In addition, Preferred Terms (PT) and System Organ Classes (SOC) will also be entered 
into databases. 
 A treatment emergent adverse event (TEAE) is an adverse event that was not present prior to but 
emerges after IMP treatment. This includes the following: 
• 
An event already present prior to IMP treatment that, after having been absent immediately prior 
to IMP treatment, re-emerges during IMP treatment 
• 
An adverse event already present prior to IMP treatment that worsens in severity during IMP 
treatment compared to before treatment. 
 TEAE will be used for analysis. All adverse events including non-TEAEs are to be presented in a table. 
 TEAEs are to be tabulated by treatment group. The number (percentage) of subjects with TEAEs is to 
be tabulated by SOC and PT. A single adverse event reworded to a MedDRA term is occasionally reported 
multiple times in one subject. In such cases, the subject is counted as one when tabulating the number of 
subjects with the particular adverse event. Additionally, the number (percentage) of subjects with TEAEs is 
to be tabulated by the highest severity (mild, moderate or severe). 
 Furthermore, the number (percentage) of subjects with TEAEs is to be tabulated by causal relationship 
(related, not related). 
 
9.7.1.8.3  Laboratory test values 
 Laboratory values are to be tabulated using the SI units. 
 Summary statistics for continuous variables are to be calculated for measurements at each Visit and 
their change from baseline by treatment group. For sequential categorical variables, laboratory values are 
to be categorised into under normal range (L), within normal range (N), or over normal range (H). Then, 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 70 of 80  
 
the number of subjects and percentage by LNH categories are presented in a shift table (baseline vs each 
visit post-dose). In addition, post-dose maximum and minimum values are to be similarly presented in a 
shift table. 
 
9.7.1.8.4   Vital signs 
 Summary statistics for vital signs (systolic blood pressure, diastolic blood pressure, pulse rate, 
temperature and weight) and their change from baseline at each evaluation time are to be calculated for 
each evaluation time and for each treatment group. 
 
9.7.1.8.5   ECG 
 The numbers of subjects having normal and abnormal standard 12-lead ECG and their percentages are 
to be presented in a shift table for each treatment group. 
 
9.7.1.8.6   Immunogenicity 
 Immunogenicity analysis is to be conducted using the safety analysis target set. The frequency and rate 
of serum anti-E6011 antibody expression at each evaluation time are to be calculated for each treatment 
group. If anti-E6011 antibodies are confirmed, frequency and ratio of their neutralizing activity (if present) 
and isotypes are to be calculated. 
 
9.7.1.8.7   Other special tests 
<Neurological symptoms> 
 The numbers of subjects having a normal and an abnormal result and their percentages are to be 
presented in a shift table for each treatment group. 
 
 < Blood CD4+ cell count > 
 Summary statistics for CD4+ cell count and change from baseline at each evaluation time are to be 
calculated for each treatment group and evaluation time. Additionally, values are to be categorised into 
under normal range (L), within normal range (N), and over normal range (H) and presented for each 
treatment group in a shift table. 
 
9.7.1.9   Other analyses 
 <Anti-JCV antibodies> 
 Specific analytical methods are described in the statistical analysis plan. 
 
9.7.1.10   Analysis of the entire dosing period 
 The same efficacy, pharmacokinetic, biomarker, immunogenicity, and safety analyses performed for 
the remission-induction period are to be performed. 
 
9.7.1.11   Analysis of the follow-up period 
 The numbers of subjects with and without PML and their percentages are to be presented in a shift 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 71 of 80  
 
table for each treatment group. The same safety analysis performed for the remission-induction period is to 
be performed. 
 
9.7.2   Target sample size 
 The number of subjects in this clinical trial was determined considering stimulation-generated 
operating characteristics relating to efficacy assessment, based on efficacy outcomes of the 101 trial and of 
similar drugs. With 20 subjects allotted to each group, if the actual difference in CR100 response rate 
between the E6011 group and placebo group is 40% or more, the probability of confirming the efficacy of 
E6011 is above 80%. 
The number of enrolled subjects was 25 at the end of the recruitment. Therefore, the sample size will be 
reduced to 25 subjects, but the analysis plan will remain unchanged and performed in accordance with 
section 9.7 Statistical method. 
 
9.7.3   Interim analysis 
 No interim analysis is planned in this clinical trial. 
 
9.7.4   Other key statistical and analytical considerations 
 Not applicable. 
 
9.7.5   Changes to the analysis plan 
 If the analysis plan needs to be changed after the start of the clinical trial, the Sponsor shall determine 
the effect the change(s) will have on the clinical trial and the method of applying the change(s). Details of 
the change are to be outlined in the Clinical Study Report. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 72 of 80  
 
10.  List of cited literature 
1   Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, et al. Development of the 
Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011; 17: 1415-22. 
2   Hisamatsu T., Hibi T. Biologics in Current Therapy for Inflammatory Bowel Disease. Jpn. J. Clin. 
Immunol. 2009; 32(3):168-79. 
3   S Ben-Horin and Y Chowers. Review article: loss of response to anti-TNF treatments in Crohn’s 
disease. Aliment Pharmacol Ther. 2011; 33:987-995. 
4   Imai T, Nishimura M, Nanki T, Umehara H. Fractalkine and inflammatory diseases. Jpn. J. Clin. 
Immunol. 2005:28;131-39. 
5   Yasuda N, Kuboi Y, Imai T. Therapeutic potential of fractalkine-targeting drugs for inflammatory 
bowel diseases. BIO Clinica. 2015; 30:54-59. 
6   Brand S, Hofbauer K, Dambacher J, Schnitzler F, Staudinger T, Pfennig S, et al. Increased expression 
of the chemokine fractalkine in Crohn’s disease and association of the fractalkine receptor T280M 
polymorphism with a fibrostenosing disease Phenotype. Am J Gastroenterol. 2006; 101:99-106. 
7   Sans M, Danese S, de la Motte C, de Souza HSP, Riv.era-Reyes BM, West GA, et al. Enhanced 
recruitment of CX3CR1 + T cells by mucosal endothelial cell-derived fractalkine in inflammatory 
bowel disease. Gastroenterol. 2007; 132:139 -53. 
8   Grip O, Bredberg A, Lindgren S, Henriksson G. Increased subpopulations of CD16 + and CD56 + 
blood monocytes in patients with active Crohn’s disease. Inflamm Bowel Dis. 2007; 13:566-72. 
9   K obayashi T, Okamoto S, Iwakami Y, Nakazawa A, Hisamatsu T, Chinen H, et al. Exclusive increase 
of CX3CR1 + CD28 - CD4 + T cells in inflammatory bowel disease and their recruitment as 
intraepithelial lymphocytes. Inflamm Bowel Dis. 2007; 13:837-46. 
10  Crohn's Disease Guidelines (revised Jan 2017). Research on Rare and Intractable Diseases “Annual 
report of the research committee of inflammatory bowel disease, the Ministry of Health and Welfare of 
Japan” (Suzuki Group) 2016. 
11   Fernando G, Axel D, Vito A, Herbert T, Gert Van A, et al. 3rd European Evidence-based Consensus 
on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical 
Management. ECCO Guideline/Consensus Paper., Journal of Crohn's and Colitis, 2017, 3–25. 
12   European medicines Agency. Guideline on the development of new medicinal products 4 for the 
treatment of Crohn’s Disease. Draft. 21 July 2016. 
13   R. Khanna, G. Zou, G. D’Haens, B. G. Feagan, W. J. Sandborn, M. K. Vandervoort. et al. A 
retrospective analysis: the development of patient reported outcome measures for the assessment of 
Crohn’s disease activity. Aliment Pharmacol Ther 2015; 41: 77–86. 
14   Laurent Peyrin-Biroulet, Julián Panés, William J. Sandborn, Séverine Vermeire, Silvio Danese, Brian 
G. Feagan et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future 
Directions. Clinical Gastroenterology and Hepatology. 2016; 14:348–354. 
15   Koutroumpakis E, Katsanos KH. Implementation of the simple endoscopic activity Score in Crohn’s 
disease. Scandi J Gastroenterol. 2016:22;133-191. 
16   FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 73 of 80  
 
(PML) associated with Tysabri (natalizumab). Safety Announcement. 01-20-2012 
17   Goda S, Imai T, Yoshie O, Yoneda O, Inoue H, Nagano, et al. CX3C-chemokine, 
fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and 
-independent mechanisms. J Immunol. 2000; 164; 4313-20. 
18   Progressive Multifocal Leukoencephalopathy PML) Treatment Guidelines 2017 Health Labour 
Sciences Research Grant, Research on Measures for Intractable Diseases, etc. “Research on prion 
diseases and latent viral infections” Research Group. 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 74 of 80  
 
 
11.  Procedures and instructions (action plan) 
11.1   Changes in the clinical trial protocol 
 Principal Investigators or Sub-investigators must not make any changes to the protocol without the 
Sponsor’s prior written agreement. 
 Changes relating to the safety of subjects, scope of assessments, or scientific quality of the clinical trial 
require notification to the public health authority or regulatory authorities, and the approval of every 
IRB/IEC involved in this clinical trial. Provided, however, that this shall not apply to cases where such 
changes in the clinical trial protocol arise under medically unavoidable circumstances, such as to avoid 
urgent risk to the subject. In the event the protocol was not followed for safety reasons, the Principal 
Investigator or a Sub-investigator shall give prompt notice of the fact to the Sponsor and the clinical trial 
centre’s IRB/IEC. The Sponsor will report the incident to regulatory authorities in accordance with the 
regulations of the region. 
 Revisions that are strictly administrative changes do not necessarily require notification to the public 
health authority or regulatory authorities, and the approval of every IRB/IEC involved in this clinical trial. 
Provided, however, that the Sponsor shall notify the IRB/IEC and regulatory authorities (or, in accordance 
with the regulations of the region, the head of the clinical trial centre) as necessary using a document 
containing the details of such changes. 
 
11.2   Conformity to the clinical trial protocol 
 Principal Investigators and Sub-investigators shall conduct this clinical in compliance with the clinical 
trial protocol (see ICH GCP, Section 4.5). 
 
11.3   Monitoring procedures 
 In addition to visiting clinical trial centres, monitors shall communicate with Principal Investigators, 
Sub-investigators, and other designated trial personnel by phone, mail, or email. Monitors are to visit 
clinical trial centres in accordance with the monitoring procedures. Principal Investigators (or the directors 
of clinical trial centres as required by regulations of each region) shall accept monitors’ actual visits to 
check the status of compliance with ICH GCP and regional regulations. Furthermore, case report forms 
and medical records (source documents) of the corresponding subjects must be readily available to be 
verified by Sponsor’s representatives. Source data verification is to be performed in accordance with 
regulations of each region to confirm protocol compliance status and data accuracy. All records at clinical 
trial centres are subject to audit by regulatory authority of each region and the IRB/IEC. 
 Based on ICH GCP (Section 1.52), source documents include, but are not limited to, the following: 
• 
Medical records of examining rooms, administrative offices, and hospitals 
• 
Certified copies or transcriptions of documents recorded by healthcare professionals 
• 
Records of auto-recording devices [e.g., Interactive Voice/Web Response System (IVRS/IWRS), 
X-rays, ultrasound tests, CTs, MRIs, radiographic images, ECGs, EEGs, sleep polygraphs, lung 
capacity tests, as well as microfiches and photographic negatives regardless of the preservation 
method] 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 75 of 80  
 
• 
Questionnaires on pain, QOL, and medical history filled out by subjects 
• 
Telephone communication records 
• 
Patient Diaries or self-evaluation checklist 
• 
Records of IMP provided and quantity checks retained by the Pharmacy Department or study 
personnel 
• 
Laboratory test results and other forms of lab test-related result (e.g., a result of urine pregnancy 
test and an urine soaked dipstick) 
• 
Records of communication between physicians or with the IRB/IEC regarding trial subject’s 
treatment 
• 
A part of data recorded in case report forms that was directly entered by subjects (e.g., 
questionnaires) 
• 
Electronic patient reported outcomes entered by subjects 
 
11.4   Data recording 
 Suitable and authorised individuals shall create a case report form for each subject who gave consent. 
All data contained in case report forms must be consistent with the source documents, except when data 
directly recorded in case report forms is regarded as the source data. When correcting data in case report 
forms, change history must be left clearly with the date of correction, and the person making the correction, 
the reason for correction, and the data before the correction must remain legible. Only the required data as 
specified in the protocol shall be recorded in case report forms. 
 Once signed, the Principal Investigator shall submit case report forms to the Sponsor and retain their 
copies. 
 For the number of liquid or very soft stools, degree of abdominal pain, and subjective general status 
among the CDAI assessment items and PRO2, the data entered by subjects in the electronic patient 
reported outcomes are to be used for evaluations. These data cover various health aspects that are 
evaluated and directly given by subjects; as such, they will not be interpreted by Principal Investigators or 
Sub-investigators. 
 
11.5   Source data specification 
 All data contained in case report forms must be consistent with the source documents. If the following 
items not recorded in medical records, including charts then case report forms constitute source data for 
these items. 
• 
IMP administration status (e.g., reason for discontinued administration or dosage change) 
• 
Reason for prior treatments and concomitant treatments (including drug and non-drug therapies) 
• 
Discontinuation-related information (e.g., subject stopped coming in for visits) 
• 
AE-related information (e.g., seriousness, causal relationship with the IMP) 
• 
CDAI 
• 
PRO2 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 76 of 80  
 
11.6   Retention of records 
 It is Principal Investigators’ (or, in accordance with regulations of each region, the heads of clinical 
trial centres or persons designated by them) responsibility to retain, even if the trial has ended or been 
discontinued, all trial-related documents including but not limited to: the clinical trial protocol, copies of 
case report form data, investigator’s brochure, documents submitted to regulatory authorities (e.g., the 
informed consent form, records of communication with IRB/IEC). Additionally, once trial databases are 
locked, the Sponsor is to provide Principal Investigators the list showing each subject’s treatment group. 
Clinical trial centres shall retain trial-related documents for at least two years after the final approval in 
ICH regions and until such time that the application is no longer under review in ICH regions; or until 
three years have passed after the development of the test drug is officially discontinued. 
 As the documents may need to be retained even after the above retention period has elapsed, Principal 
Investigators shall discuss with the Sponsor whether or not to destroy the documents. Principal 
Investigators, even if they were to retire or resign from their positions, shall discuss with the Sponsor ways 
to retain the documents. 
 The test drug is expected to receive the biological product designation. For retrospective study-purposes, 
clinical trial centres shall maintain and manage the documents identifying each “subject’s name, address, and 
IMP administration dates/lot numbers” for at least 10 years from the date of the final dose. 
 
11.7   Audit procedures and inspections 
 In addition to the regular monitoring procedures, the Sponsor’s auditing staff will perform audits in 
accordance with the Sponsor's SOP to verify that ICH GCP and regulations of each region are being fully 
adhered to. Additionally, if the regulatory authority requests an inspection during or after the clinical trial, 
the Principal Investigator shall immediately notify the Sponsor of this fact. 
 
11.8   IMP handling 
 The Sponsor is to provide the IMP to clinical trial pharmacists. The IMP provided must be kept in 
appropriate storage space (e.g. a locked cabinet) and stored under the specified conditions. Clinical trial 
pharmacists must accurately record the status of IMP delivery and use in the IMP Accountability Log. If 
requested, a copy of the IMP Accountability Log must be submitted to the Sponsor at the end of the 
clinical trial. An accurate record of the dates and quantities of IMP prescribed to each subject must be 
presentable at the time of investigation or inspection. After the IMP has been delivered to clinical trial 
centres, monitors are to verify the documents as well as all other trial-related documents as needed. 
 The IMP is provided for the clinical trial only and must not be used for any other purposes. Clinical 
trial pharmacists must dispose of unused portions of the IMP without the Sponsor’s permission. At the end 
of the trial or as appropriate during the trial, clinical trial pharmacists shall return all unused bottles of the 
IMP and, if requested, provide a copy of the Drug Accountability Log containing complete information to 
the Sponsor (or predesignated person) (except when the Sponsor has approved of disposal at each clinical 
trial centre). 
 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 77 of 80  
 
11.9   Public release of the clinical trial results 
 Any manuscripts, summaries and other documents based on the results of this clinical trial that are to 
be presented must first be reviewed and approved in writing by the Sponsor. This review is conducted in 
order to protect Sponsor’s proprietary information that existed at the start of the clinical trial or arises 
during the clinical trial. 
 The details of necessary duties pertaining to public release of any data, documents based on the clinical 
trial results, and other information that arises or is created are to be outlined in the agreement made by and 
entered into between the Principal Investigator and the Sponsor or CRO. 
 
11.10   Disclosure of information/results and confidentiality 
 Principal Investigators, Sub-investigators, trial coordinators and IRB/IEC members are obliged to keep 
confidentiality of the information contained in the clinical trial protocol and its revisions, as well as any 
results obtained during the trial. Full or partial disclosure must first be agreed to by the Sponsor in writing 
and only be used for reviewing or conducting the clinical trial. Data collected as part of this clinical trial 
may not be used in any literary work including publications without the Sponsor’s written agreement. 
These duties related to non-disclosure and non-use must not reduce the duties stipulated in the 
non-disclosure agreement made between the Sponsor (or CRO) and the Principal Investigator/head of 
clinical trial centre. 
 Every member involved in the conduct of this clinical trial must adhere to these duties related to 
non-disclosure and non-use stipulated in the non-disclosure agreement made between the Sponsor (or 
CRO) and the Principal Investigator/head of clinical trial centre. 
 
11.11   Discontinuation of clinical trial 
 The Sponsor may discontinue the clinical trial for medical reasons. The Sponsor also has the right to 
discontinue the clinical trial at any time for any reason. The Sponsor must promptly notify Principal 
Investigators/heads of clinical trial centres and regulatory authorities of discontinuation or suspension and 
the reason thereof. The Sponsor or Principal Investigators/heads of clinical trial centres must also promptly 
notify the IRB/IECs of discontinuation or suspension and the reason thereof in accordance with applicable 
regulations. 
 Principal Investigators may discontinue the clinical trial whenever they deem it necessary. If Principal 
Investigators discontinue or suspend the trial without the Sponsor’s prior consent, they shall notify the 
heads of the clinical trial centres of this fact (if necessary) and Principal Investigators/heads of clinical trial 
centres shall promptly notify the IRB/IECs of this fact. Principal Investigators/heads of clinical trial 
centres shall provide the Sponsor and the IRB/IECs a detailed explanation of discontinuation or suspension 
in writing. Furthermore, trial-related documents must be saved in accordance with the stipulations of 
“Retention of records.” 
 
11.12   Compensation for health damages 
 The Sponsor shall be insured in accordance with guidelines and regulations of the country in which the 
clinical trial is conducted to cover the liability for subjects. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 78 of 80  
 
12.  Appendix 
 Appendix 1 Collection, handling, use, storage and security of samples for 
pharmacodynamic, pharmarcogenomic, and biomarker evaluations and protection of 
subjects’ privacy 
 Samples from subjects enrolled in this clinical trial will be collected to perform pharmacodynamic, 
pharmarcogenomic, and biomarker analyses. The collected samples will be used for assessments and 
validations and have an important role in identifying biomarkers that are useful in predicting results related 
to therapeutic response and/or safety, as well as the sequence of transcriptional regulatory regions of such 
gene expression biomarkers; they are also useful in developing diagnostic drugs. 
 The collection of samples used for pharmacodynamic, pharmarcogenomic, and biomarker evaluations 
shall be made conforming to the sample processing procedures outlined in the clinical trial protocol and, 
unless the collection and use of samples are prohibited by regulatory requirements, in accordance with the 
stipulations of the clinical trial protocol. 
 
 Sample collection and handling 
Pharmacogenomic samples and biomarker samples shall be collected when indicated by the study 
schedule. If blood samples to be used for pharmacogenomic testing and biomarker testing cannot be collected 
when indicated by the study schedule for practical or medical reasons, they may be collected during other 
hospital visits based on the judgement of the Principal Investigator or clinical trial centre staff. 
 
 Security, use and storage of samples 
 DNA extraction and other sample processing and DNA methylation are to be done at testing centres 
according to the Sponsor’s instructions. Samples are to be processed, analysed and stored at appropriate 
testing centres to ensure data reliability and protection of subject privacy. 
 The use of samples is restricted within the scope specified in the clinical trial protocol. Testing centres 
have no authority to go beyond the scope required to conduct the prescribed analyses or the right to hand 
over the samples. The Sponsor will never hand over the samples to a third party. 
 The samples will be stored for no more longer than three years after the end of the clinical trial. At the 
end of the storage period, samples will be destroyed. When regulatory authorities (or medical product 
approval bodies) have inquiries about this clinical trial, the samples may be stored for a longer period. 
Under such special circumstances, the samples are to be stored until such time that the inquires have been 
properly addressed. 
 The advancement of research and technology can potentially lead to identification of gene mutations of 
interest or unanticipated alternative genetic analysis techniques. It is impossible to predefine all potential 
analyses that may be conducted in the future. Accordingly, all collected (according to ICH E18 draft 
guidelines) samples will be single-coded or double-coded to protect the privacy of the subjects. 
 
 Right to withdraw consent 
 Whenever subjects wish to withdraw their consent to participating in the evaluation during the sample 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 79 of 80  
 
storage period, the Sponsor will destroy their samples. Provided however, all the results of analysis 
performed up to the point of consent withdrawal will be used as needed to maintain the integrity of the 
evaluation project. 
 
 Subject privacy and data disclosure 
 Samples will be single-coded or double-coded and will not carry personal identifiers (e.g., initials, date 
of birth, public ID number). Double-coding refers to labelling initially with one code (subject ID), then 
with the second code. It is possible to identify the individual subject with the use of both coding keys. 
These coding keys are typically maintained by different managers. Coding keys that link sample IDs to 
subject IDs will be stored separately from the samples. At this point, samples become double-coded and 
the initial code becomes the subject ID. Testing centre operators who conduct genetic testing will never 
access the coding keys. Clinical data collected as part of the clinical trial does not contain information that 
can identify the individual subject. Clinical data can be linked by using sample ID coding keys. 
 
 The Sponsor will ensure data protection and take as many steps as possible to maintain confidentiality. 
The data on subjects enrolled in the clinical trial may be analysed in all global regions, regardless of where 
their samples were collected. 
 The Sponsor and their representatives and agents may share coded data with the following 
organizations and their members that conduct the evaluations and audits: 
• 
Clinical trial centres 
• 
CRO under contract with the Sponsor 
• 
IRB/IECs/IECs involved in the evaluations 
• 
Regulatory authorities or relevant public agencies 
 
 After the completion of the analysis, the results will be documented in a separate report, and partial or 
complete coded data will be included in lists or tables. Other publications (e.g., peer-reviewed scientific 
journals) and public presentations of the clinical trial results may contain summaries of the study 
population, but will never release any results that may be able to identify the individual subjects. 
 
 Considering the nature of evaluation of pharmacodynamic, pharmarcogenomic, and biomarker analysis 
results, it is not possible to disclose the individual subject data to a given subject. It is unlikely that any 
results obtained in the analysis would have an immediate clinical significance to the subjects (patients) or 
their family. For this reason, the results obtained in the analysis will not be disclosed to the subjects 
(patients) or their attending physicians. 

 
 EA Pharma Co., Ltd.  
 E6011-ET2  
 
Date: 18-Apr-2022 version 11.0 
 Confidential   
  
 Page 80 of 80  
 
 
13.  Attachments 
 Attachment 1  Clinical trial centres and Principal Investigators (Applicable to Japan, separate 
document outside the protocol for Europe) 
 Attachment 2  Clinical trial framework 
 Attachment 3  Reference criteria for determining severity levels of laboratory values  
 Attachment 4  IMP preparation procedure  
 Attachment 5  IMP types, packaging and labelling (Labelling applicable to Japan, separate document 
outside the protocol for Europe)  
 Attachment 6  List of prohibited/restricted concomitant drugs  
 Attachment 7  Criteria for insufficient therapeutic response with the existing drugs (steroids and 
immunomodulators) pertaining to inclusion criterion 5 
Attachment 8  Criteria for primary nonresponse, secondary nonresponse and intolerance with 
biologics pertaining to inclusion criterion 5 
 Attachment 9  Criteria for steroid dosage reduction schedule 
 Attachment 10  CDAI Score Sheet 
 Attachment 11  Evaluation of disease activity by PRO2 
 Attachment 12  Endoscopic evaluation by SES-CD 
 Attachment 13  Neurological symptoms check list   
 Attachment 14  Abnormal neurological symptoms report 
 Attachment 15  Pregnancy report 
 Attachment 16  Pregnancy outcome 
 Attachment 17  Information on medical devices (blood-collecting tubes, etc.) not approved in Japan 
(Applicable to Japan)  
 Attachment 18  Report of defective medical devices not approved in Japan (Applicable to Japan)